#  @EgidiusLambrech E Lambrechts E Lambrechts posts on X about $gmab, $jnj, $abbv, $pfe the most. They currently have [------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours. ### Engagements: [-----] [#](/creator/twitter::404367469/interactions)  - [--] Week [---] +20% - [--] Month [------] +623% - [--] Months [------] +25% - [--] Year [------] -8.20% ### Mentions: [--] [#](/creator/twitter::404367469/posts_active)  - [--] Month [--] +69% - [--] Months [---] +120% - [--] Year [---] +75% ### Followers: [------] [#](/creator/twitter::404367469/followers)  - [--] Week [---] -0.29% - [--] Month [---] no change - [--] Months [---] no change - [--] Year [---] +2.10% ### CreatorRank: [---------] [#](/creator/twitter::404367469/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [countries](/list/countries) [finance](/list/finance) [currencies](/list/currencies) [technology brands](/list/technology-brands) [social networks](/list/social-networks) [us election](/list/us-election) [cryptocurrencies](/list/cryptocurrencies) [travel destinations](/list/travel-destinations) [exchanges](/list/exchanges) **Social topic influence** [$gmab](/topic/$gmab) #2, [$jnj](/topic/$jnj), [$abbv](/topic/$abbv) #48, [$pfe](/topic/$pfe), [$gmxay](/topic/$gmxay), [target](/topic/target), [$sgen](/topic/$sgen), [$nvs](/topic/$nvs), [acasunlimab](/topic/acasunlimab), [$nvo](/topic/$nvo) **Top assets mentioned** [Johnson & Johnson (JNJ)](/topic/$jnj) [AbbVie Inc (ABBV)](/topic/$abbv) [Pfizer, Inc. (PFE)](/topic/$pfe) [Seagen Inc (SGEN)](/topic/$sgen) [Novartis AG (NVS)](/topic/$nvs) [Novo-Nordisk (NVO)](/topic/$nvo) [Merus N.V. Common Shares (MRUS)](/topic/$mrus) [Amgen, Inc. (AMGN)](/topic/$amgn) [Frontline Ltd. (FRO)](/topic/$fro) [Halozyme Therapeutics, Inc. (HALO)](/topic/$halo) [Morgan Stanley (MS)](/topic/morgan-stanley) [Bank of America (BAC)](/topic/bank-of-america) [Sanofi (SNY)](/topic/sanofi) [AstraZeneca PLC (AZN)](/topic/$azn) [ROGin AI (ROG)](/topic/$rog) [Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP)](/topic/$hznp) ### Top Social Posts Top posts by engagements in the last [--] hours "Teprotumumab is a fully human antibody developed by/with #Genmab $GMXAY Horizon Pharma Announces Phase [--] Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease (TED) Met Primary and All Secondary Endpoints https://www.businesswire.com/news/home/20190228005255/en/Horizon-Pharma-plc-Announces-Phase-3-Confirmatory#.XHftc6htgA8.twitter https://www.businesswire.com/news/home/20190228005255/en/Horizon-Pharma-plc-Announces-Phase-3-Confirmatory#.XHftc6htgA8.twitter" [X Link](https://x.com/EgidiusLambrech/status/1101125770066448386) 2019-02-28T14:23Z [---] followers, [--] engagements "Nice interview with the charismatic #Genmab CEO Jan van de Winkel (in english) $GMXAY #daratumumab https://play.borsen.dk/klip/5c72d71a595ab4f00a32f5b8 https://play.borsen.dk/klip/5c72d71a595ab4f00a32f5b8" [X Link](https://x.com/EgidiusLambrech/status/1101492042906169345) 2019-03-01T14:39Z [---] followers, [--] engagements "#Tisotumab vedotin is being developed in collaboration with @Genmab #pipeline #Cervical Cancer $GMXAY" [X Link](https://x.com/EgidiusLambrech/status/1111620324595023872) 2019-03-29T13:25Z [---] followers, [--] engagements "New @Genmab #Duobody trial : GEN1046 Safety Trial in Patients With Malignant Solid Tumors GEN1046 = DuoBody PD-L1x4-1BB in collaboration with BioNTech $GMXAY https://clinicaltrials.gov/ct2/show/NCT03917381term=NCT03917381&rank=1 https://clinicaltrials.gov/ct2/show/NCT03917381term=NCT03917381&rank=1" [X Link](https://x.com/EgidiusLambrech/status/1118516643599212550) 2019-04-17T14:08Z [---] followers, [--] engagements "Novel Agent Reduces Bulging Eyes in Thyroid Eye Disease / Graves' orbitopathy #Teprotumumab is a fully human antibody developed by #Genmab. Clinical development now conducted by #Horizon Pharma. $GMXAY #Royalties https://www.medpagetoday.com/meetingcoverage/aace/79493 https://www.medpagetoday.com/meetingcoverage/aace/79493" [X Link](https://x.com/EgidiusLambrech/status/1122844189719449600) 2019-04-29T12:44Z [---] followers, [--] engagements "#Daratumumab as Frontline Treatment for Multiple #Myeloma - by Dr. @szusmani #Genmab $GMXAY $JNJ via @YouTube @TargetedOnc https://youtu.be/le6XDnI0wAE https://youtu.be/le6XDnI0wAE" [X Link](https://x.com/EgidiusLambrech/status/1123943667180371968) 2019-05-02T13:33Z [---] followers, [--] engagements "good news for #Genmab as [--] of these potential blockbusters use Genmab's DuoBody technology the BCMA/CD3 (JNJ-7957) and the EGFR + cMet (JNJ-6372). I think on the second Genmab may even get double #royalties as I think they made both arms $JNJ $GMXAY J&J polishes up its new list of late-stage blockbuster candidates and cancer remains big $JNJ https://t.co/aipHhfCmSj J&J polishes up its new list of late-stage blockbuster candidates and cancer remains big $JNJ https://t.co/aipHhfCmSj" [X Link](https://x.com/EgidiusLambrech/status/1128682230086275074) 2019-05-15T15:23Z [---] followers, [--] engagements "#Genmab products featured in the Johnson & Johnson [----] Pharmaceutical Business Review. Offcourse Darzalex and [--] #DuoBody antibodies [--] of which are mentioned as $ [--] billion potential #royalties $GMXAY $JNJ #Daratumumab" [X Link](https://x.com/EgidiusLambrech/status/1129009900380741633) 2019-05-16T13:05Z [---] followers, [--] engagements "#Genmab #Daratumumab $GMXAY $JNJ #Darzalex #Myeloma" [X Link](https://x.com/EgidiusLambrech/status/1129010867117465601) 2019-05-16T13:09Z [---] followers, [--] engagements "#Genmab #DuoBody platform being used by Johnson & Johnson $GMXAY $JNJ #Daratumumab #Myeloma #royalties" [X Link](https://x.com/EgidiusLambrech/status/1129011807300067328) 2019-05-16T13:12Z [---] followers, [--] engagements "Apparantly the CD33xCD3 is also a #Genmab #DuoBody it was just updated on the Genmab website It also shows another one JNJ-63898081 for #Prostate Cancer #Solid tumors So now [--] Genmab duobodies in development by Johnson & Johnson $JNJ $GMXAY #ASCO19 http://www.genmab.com/product-pipeline/products-in-development #Genmab products featured in the Johnson & Johnson [----] Pharmaceutical Business Review. Offcourse Darzalex and [--] #DuoBody antibodies [--] of which are mentioned as $ [--] billion potential #royalties $GMXAY $JNJ #Daratumumab https://t.co/wrbV1V5Uey" [X Link](https://x.com/EgidiusLambrech/status/1129288703321546752) 2019-05-17T07:33Z [---] followers, [--] engagements "Another new $JNJ trial using #Genmab #DuoBody technology this time in #Solid tumors #prostate cancer. A Study of JNJ-63898081 in Participants With Advanced Stage #Solid Tumors $GMXAY https://clinicaltrials.gov/ct2/show/NCT03926013 http://GEN.CO https://clinicaltrials.gov/ct2/show/NCT03926013 http://GEN.CO" [X Link](https://x.com/EgidiusLambrech/status/1131563141048020992) 2019-05-23T14:10Z [---] followers, [--] engagements "Phase [--] #COLUMBA Study Investigating a #Subcutaneous Formulation of DARZALEX (#daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple #Myeloma #Genmab #asco19 $JNJ $GMXAY https://www.janssen.com/phase-3-columba-study-investigating-subcutaneous-formulation-darzalex-daratumumab-showed-non https://www.janssen.com/phase-3-columba-study-investigating-subcutaneous-formulation-darzalex-daratumumab-showed-non" [X Link](https://x.com/EgidiusLambrech/status/1135445754212966400) 2019-06-03T07:18Z [---] followers, [--] engagements "#Daratumumab approval in China @Genmab $GMXAY $GMAB $JNJ http://www.nmpa.gov.cn/WS04/CL2056/338825.html Darzalex(Daratumumab) a CD38-directed cytolytic antibody was approved by NMPA as monotherapy for the treatment of relapsed or refractory multiple myeloma patients who have received prior therapies including a proteasome inhibitor and an immunomodulatory agent. https://t.co/qaTdiCZ4hD http://www.nmpa.gov.cn/WS04/CL2056/338825.html Darzalex(Daratumumab) a CD38-directed cytolytic antibody was approved by NMPA as monotherapy for the treatment of relapsed or refractory multiple myeloma patients" [X Link](https://x.com/EgidiusLambrech/status/1147062903826255877) 2019-07-05T08:41Z [---] followers, [--] engagements "SMC recommends #Darzalex as second-line treatment for multiple #myeloma (The Scottish Medicines Consortium) #daratumumab #Genmab $GMXAY $GMAB $JNJ via @Pharmafield https://pharmafield.co.uk/pharma_news/smc-recommends-darzalex-as-second-line-treatment-for-multiple-myeloma/ https://pharmafield.co.uk/pharma_news/smc-recommends-darzalex-as-second-line-treatment-for-multiple-myeloma/" [X Link](https://x.com/EgidiusLambrech/status/1148232898585202696) 2019-07-08T14:10Z [---] followers, [--] engagements "#Teprotumumab is a fully human antibody developed by #Genmab. Clinical development now conducted by #Horizon Pharma. #Graves' orbitopathy #ThyroidEyeDisease $GMXAY $GMAB #Royalties NEWS: Today we announced that weve submitted a Biologics License Application (BLA) to the FDA for our investigational medicine for the treatment of active #ThyroidEyeDisease (TED). Read the full press release here: https://t.co/xUBjbpGR25. https://t.co/UCcczaL0nA NEWS: Today we announced that weve submitted a Biologics License Application (BLA) to the FDA for our investigational medicine for the treatment of active" [X Link](https://x.com/EgidiusLambrech/status/1148913904124346369) 2019-07-10T11:16Z [---] followers, [--] engagements "Morgan Stanley raises EPS estimates for #Genmab Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and $31 price target on $GMAB and raised his EPS estimates for FY20 and FY21. https://thefly.com/landingPageNews.phpid=3048529 https://thefly.com/landingPageNews.phpid=3048529" [X Link](https://x.com/EgidiusLambrech/status/1237733626587910144) 2020-03-11T13:34Z [---] followers, [--] engagements "#Genmab investor presentation June [----] $GMAB $JNJ $ABV $BNTX $SGEN $NVS https://ir.genmab.com/static-files/411621e5-4366-4690-84b1-081308db8a83 https://ir.genmab.com/static-files/411621e5-4366-4690-84b1-081308db8a83" [X Link](https://x.com/EgidiusLambrech/status/1273618434333585409) 2020-06-18T14:07Z [---] followers, [--] engagements "@dlacalle_IA I think one would have to look at Total GDP to make that statement you are looking at growth numbers [----] GDP was 2.445bn ; H1 [--] is already at 1.619bn. Awfull number nonetheless. https://www.destatis.de/EN/Themes/Economy/National-Accounts-Domestic-Product/Tables/lrvgr02.html https://www.destatis.de/EN/Themes/Economy/National-Accounts-Domestic-Product/Tables/lrvgr02.html" [X Link](https://x.com/EgidiusLambrech/status/1288821198655299584) 2020-07-30T12:58Z [---] followers, [--] engagements "Novo Nordisk turns up the heat on inlicensed #Genmab drug with phase III preparations #MIM8 $NVO $NOVO $GMAB #Royalties https://medwatch.com/News/Pharma___Biotech/article13308259.ece https://medwatch.com/News/Pharma___Biotech/article13308259.ece" [X Link](https://x.com/EgidiusLambrech/status/1441041832583049220) 2021-09-23T14:08Z [---] followers, [--] engagements "#Kesimpta sales Q3 '21 $109mn (YTD $225mn) #Genmab is entitled to 10% royalties on net sales of Kesimpta $NVS $NOVN.SW $GMAB #Ofatumumab" [X Link](https://x.com/EgidiusLambrech/status/1452889625194811393) 2021-10-26T06:47Z [---] followers, [--] engagements "Genmab A/S (GEN:DC) $GMAB PT Raised to DKK3200 at Bernstein via @Street_Insider https://www.streetinsider.com/Analyst+Comments/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK3%2C200+at+Bernstein/19413231.html https://www.streetinsider.com/Analyst+Comments/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK3%2C200+at+Bernstein/19413231.html" [X Link](https://x.com/EgidiusLambrech/status/1478746998589341696) 2022-01-05T15:15Z [---] followers, [--] engagements "Novo Nordisk spies great #hemophilia opportunities with partner #Genmab Mim8 is a bispecific antibody created under a collaboration between $GMAB and $NVO using Genmabs DuoBody technology and the first DuoBody candidate outside of oncology. https://medwatch.com/News/Pharma___Biotech/article13701763.ece https://medwatch.com/News/Pharma___Biotech/article13701763.ece" [X Link](https://x.com/EgidiusLambrech/status/1489223621323202561) 2022-02-03T13:05Z [---] followers, [--] engagements "$NVO $GMAB @Genmab #Mim8 Pratima Chowdary presented data on the FVIIIa mimetic Mim8 in the phase 1/2 FRONTIER-1 trial in healthy individuals and those with haemophilia A. 25% of AEs could be drug related higher dose cohorts had few bleeds. #ISTH2022 https://t.co/xjjT3KtIAJ Pratima Chowdary presented data on the FVIIIa mimetic Mim8 in the phase 1/2 FRONTIER-1 trial in healthy individuals and those with haemophilia A. 25% of AEs could be drug related higher dose cohorts had few bleeds. #ISTH2022 https://t.co/xjjT3KtIAJ" [X Link](https://x.com/EgidiusLambrech/status/1546507630931329030) 2022-07-11T14:52Z [---] followers, [--] engagements "#Epcoritamab $GMAB $ABBV #Genmab #AbbVie New clinical trial: A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma https://t.co/HtWwyP8kN4 #DLBCL #lymsm #hematology New clinical trial: A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma https://t.co/HtWwyP8kN4 #DLBCL #lymsm" [X Link](https://x.com/EgidiusLambrech/status/1546808207330496513) 2022-07-12T10:46Z [---] followers, [--] engagements "Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2900 at Barclays via @Street_Insider https://www.streetinsider.com/Analyst+Comments/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C900+at+Barclays/20338159.html https://www.streetinsider.com/Analyst+Comments/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C900+at+Barclays/20338159.html" [X Link](https://x.com/EgidiusLambrech/status/1549286585467912193) 2022-07-19T06:54Z [---] followers, [--] engagements "@FiercePharma any idea what happened to the earlier deal with Halozyme Therapeutics with the same purpose (coincidentally exactly to the day 2yrs ago.indicating perhaps that contract had some 2yr clause) https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-and-halozyme-therapeutics-inc-enter https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-and-halozyme-therapeutics-inc-enter" [X Link](https://x.com/EgidiusLambrech/status/1597297958839459841) 2022-11-28T18:34Z [---] followers, [--] engagements "of interest to #Genmab as they share a 50:50 partnership on #Tivdak (Tisotumab Vedotin) $GMAB $SGEN" [X Link](https://x.com/EgidiusLambrech/status/1635277176269570050) 2023-03-13T13:50Z [---] followers, [---] engagements "of interest to #Genmab for Provention Bio asset PRV-015 for Celiac Disease (PRV-015 was initially developed by Genmab as HuMax-IL15) $GMAB" [X Link](https://x.com/EgidiusLambrech/status/1635277322797584387) 2023-03-13T13:51Z [---] followers, [---] engagements "Reid Merryman MD on High-Risk Follicular Lymphoma: New Data on #Epcoritamab Rituximab and Lenalidomide #Genmab #AbbVie $GMAB $ABBV" [X Link](https://x.com/EgidiusLambrech/status/1668955444147265536) 2023-06-14T12:16Z [---] followers, [--] engagements "Frontline Treatment With #Epcoritamab Plus R-CHOP for Patients With High-Risk DLBCL - Updated EPCORE NHL-2 Data #Genmab #AbbVie $GMAB $ABBV" [X Link](https://x.com/EgidiusLambrech/status/1671081701513089024) 2023-06-20T09:05Z [---] followers, [---] engagements "Preclinical anti-tumour activity of #HexaBody-CD38 anext-generation CD38 antibody with superior complement-dependent cytotoxic activity otherwise known as 'SuperDara' 😄 @Genmab $GMAB $JNJ #Darzalex #Daratumumab" [X Link](https://x.com/anyuser/status/1674385977521913856) 2023-06-29T12:01Z [--] followers, [---] engagements "#Genmab Announces AbbVie Receives Positive #CHMP Opinion for #Epcoritamab (TEPKINLY) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) $GMAB $ABBV" [X Link](https://x.com/EgidiusLambrech/status/1682310147354312705) 2023-07-21T08:42Z [---] followers, [--] engagements "Janssen Receives Positive CHMP Opinions for Novel Bispecific Antibodies TALVEY(#talquetamab) and TECVAYLI(#teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma $JNJ $GMAB #Genmab #Royalties" [X Link](https://x.com/EgidiusLambrech/status/1682395562845302787) 2023-07-21T14:22Z [---] followers, [--] engagements "#Teclistamab #Tecvayli $GMAB #Genmab $JNJ 🚨 NEWS 🚨 @EMA_News CHMP recommends a new dosing schedule for teclistamab a BCMA/CD3-targeted bispecific antibody for the treatment of RRMM with [--] prior therapies including an IMiD PI and an anti-CD38 antibody with observed disease progression. https://t.co/mbKavMm5Nz 🚨 NEWS 🚨 @EMA_News CHMP recommends a new dosing schedule for teclistamab a BCMA/CD3-targeted bispecific antibody for the treatment of RRMM with [--] prior therapies including an IMiD PI and an anti-CD38 antibody with observed disease progression. https://t.co/mbKavMm5Nz" [X Link](https://x.com/EgidiusLambrech/status/1683810287621754884) 2023-07-25T12:03Z [---] followers, [----] engagements "U.S. #FDA Approves #TALVEY (#talquetamab-tgvs) a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple #Myeloma $JNJ $GMAB #Genmab #Royalties" [X Link](https://x.com/EgidiusLambrech/status/1689592251033276418) 2023-08-10T10:59Z [---] followers, [---] engagements "@Abdallah81MD @JanssenGlobal @sanofi @bmsnews @Amgen you might want to add @Genmab as [--] of those originated there with a possible 4th on the way with Hexabody-CD38 $GMAB" [X Link](https://x.com/EgidiusLambrech/status/1692803400478437753) 2023-08-19T07:39Z [---] followers, [---] engagements "European Commission Approves Reduced Dosing Frequency for Janssens Bispecific Antibody #TECVAYLI (#teclistamab) #Genmab $GMAB $JNJ" [X Link](https://x.com/EgidiusLambrech/status/1693539121023619221) 2023-08-21T08:22Z [---] followers, [---] engagements "$JNJ Submits Supplemental Biologics License Application to the U.S. FDA for #RYBREVANT combo (#amivantamab-vmjw) with #Chemo for #First-line Locally Advanced or Metastatic EGFR Exon [--] Insertion Mutation-Positive Non-Small Cell Lung Cancer #Genmab $GMAB" [X Link](https://x.com/EgidiusLambrech/status/1695050412389228878) 2023-08-25T12:28Z [---] followers, [---] engagements "Transcript: Johnson & Johnson at Morgan Stanley Global Healthcare Conference - Sep '23 $JNJ Also of interest for #Genmab as many products discussed are $GMAB originated; Darzalex Tecvayli Talvey and Rybrevant #Royalties https://johnsonandjohnson.gcs-web.com/static-files/0393dab9-a719-4b65-9aad-225403522a5f https://johnsonandjohnson.gcs-web.com/static-files/0393dab9-a719-4b65-9aad-225403522a5f" [X Link](https://x.com/EgidiusLambrech/status/1704113962638250394) 2023-09-19T12:43Z [---] followers, [---] engagements "Top [--] Best-Selling Drugs Of Q2 [----] - #Darzalex entered the list $JNJ $GMAB #Genmab #Royalties #Daratumumab" [X Link](https://x.com/EgidiusLambrech/status/1706296242828198108) 2023-09-25T13:15Z [---] followers, [---] engagements "#RYBREVANT and lazertinib compared to osimertinib First pivotal study to show a clinically meaningful benefit in a chemotherapy-free regimen versus osimertinib #amivantamab EGFR-Mutated Non-Small Cell Lung Cancer $JNJ $GMAB #Genmab #Royalties" [X Link](https://x.com/EgidiusLambrech/status/1707363746945933799) 2023-09-28T11:56Z [---] followers, [---] engagements "Expansion Trial of #Epcoritamab Shows Promising Antitumor Activity in Patients With High-Risk Relapsed/Refractory #CLL @Genmab $GMAB #AbbVie $ABBV via @targetedonc https://www.targetedonc.com/view/expansion-trial-of-epcoritamab-shows-promising-antitumor-activity-in-patients-with-high-risk-relapsed-refractory-cll https://www.targetedonc.com/view/expansion-trial-of-epcoritamab-shows-promising-antitumor-activity-in-patients-with-high-risk-relapsed-refractory-cll" [X Link](https://x.com/EgidiusLambrech/status/1711403600935559589) 2023-10-09T15:29Z [---] followers, [----] engagements "#AbbVie's #EPKINLY (#epcoritamab) receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to treat adult patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (#DLBCL) #Genmab $GMAB $ABBV" [X Link](https://x.com/EgidiusLambrech/status/1714242648821702926) 2023-10-17T11:31Z [---] followers, [---] engagements "@BertrandBio @Kevin_M_Biotech JNJ execs yesterday mentioned 'Our regimen is a chemo-free option for patients which we think is important' which i assume may be their selling point. Meanwhile $JNJ hardly moves and $AZN -3.3% pre-market. 🤔" [X Link](https://x.com/EgidiusLambrech/status/1714621647632609747) 2023-10-18T12:37Z [---] followers, [---] engagements "@BertrandBio @Kevin_M_Biotech yes i guess that may be the real question. curious for KOL comments over the weekend but maybe we need some extra months of data for a real answer" [X Link](https://x.com/EgidiusLambrech/status/1714624904006435027) 2023-10-18T12:50Z [---] followers, [--] engagements "UK approval for #Tepkinly (#epcoritamab) $GMAB $ABBV #Genmab #AbbVie" [X Link](https://x.com/EgidiusLambrech/status/1715331634763821506) 2023-10-20T11:38Z [---] followers, [----] engagements "Ph3 innovaTV [---] Trial Shows Potential of #Tisotumab Vedotin in #Cervical Cancer #Tivdak demonstrated a 30% reduction in the risk of death compared with investigators choice of chemotherapy $GMAB $SGEN $PFE #Genmab #Seagen #Pfizer via @targetedonc" [X Link](https://x.com/EgidiusLambrech/status/1716364110294618228) 2023-10-23T08:01Z [---] followers, [---] engagements "Professor Ignace Vergote reports on key results from ESMO Congress [----] on the innovaTV [---] trial -Recurrent or Metastatic #Cervical Cancer #Tisotumab Vedotin #Tivdak $GMAB $SGEN $PFE #Genmab #Seagen #Pfizer" [X Link](https://x.com/EgidiusLambrech/status/1716467799139201188) 2023-10-23T14:53Z [---] followers, [---] engagements "ESMO [----] Neues zu #Tisotumab Vedotin beim metastasierten Gebrmutterhalskrebs ab [--]. Linie. #Tivdak $GMAB $SGEN $PFE #Genmab #Seagen #Pfizer #ESMO23 via @YouTube" [X Link](https://x.com/EgidiusLambrech/status/1717084279656611855) 2023-10-25T07:42Z [---] followers, [---] engagements "#ESMO23 Expert video report on #amivantamab in combination therapy for 1L treatment in EGFRm advanced NSCLC #Rybrevant $JNJ $GMAB #Genmab #Royalties" [X Link](https://x.com/EgidiusLambrech/status/1718954702505652567) 2023-10-30T11:35Z [---] followers, [---] engagements "#Cervical cancer drug raises survival rate by 30% compared to chemotherapy: Game-changer #TIVDAK's bombshell results in phase [--] trial change the standard of care says lead researcher #Tisotumab $GMAB $SGEN $PFE Genmab Seagen Pfizer #ESMO23 #FoxNews https://www.foxnews.com/health/cervical-cancer-drug-increased-survival-rate-30-percent-chemotherapy-game-changer https://www.foxnews.com/health/cervical-cancer-drug-increased-survival-rate-30-percent-chemotherapy-game-changer" [X Link](https://x.com/EgidiusLambrech/status/1720022257194479819) 2023-11-02T10:17Z [---] followers, [---] engagements "#Tisotumab Vedotin for Metastatic #Cervical Cancer: Results From ESMO [----] With Brian Slomovitz MD #Tivdak $GMAB $SGEN $PFE Genmab Seagen Pfizer #ESMO23" [X Link](https://x.com/EgidiusLambrech/status/1720035162220609700) 2023-11-02T11:08Z [---] followers, [---] engagements "#Tisotumab Vedotin vs. Investigator's Choice in Cervical Cancer Dr. Slomovitz MD offers expert insights shedding light on this innovative therapy's significance in improving outcomes for patients #Tivdak $GMAB $SGEN $PFE Genmab Seagen Pfizer #ESMO23" [X Link](https://x.com/EgidiusLambrech/status/1720410506001793136) 2023-11-03T12:00Z [---] followers, [---] engagements "Subcutaneous #epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma - EPCORE NHL-3 #Epkinly $GMAB $ABBV #Genmab #AbbVie" [X Link](https://x.com/EgidiusLambrech/status/1720717540052070779) 2023-11-04T08:20Z [---] followers, [---] engagements "#Genmab's COO on launch of new cancer hope: It's gone better than expected Were seeing really strong uptake for #Epkinly says $GMAB s Chief Operating Officer Anthony Mancini. #Epcoritamab $ABBV" [X Link](https://x.com/EgidiusLambrech/status/1722159101495353700) 2023-11-08T07:48Z [---] followers, [---] engagements "$JNJ submits Supplemental Biologics License Application to U.S. FDA for Approval of #RYBREVANT (#amivantamab) + Chemotherapy for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Progressed on or after Osimertinib $GMAB #Genmab" [X Link](https://x.com/EgidiusLambrech/status/1726628947285401879) 2023-11-20T15:49Z [---] followers, [----] engagements "#Darzalex Late-Breaker @ #ASH23 #Daratumumab + Bortezomib Lenalidomide & Dexamethasone (VRd) Versus Vrd Alone in patients with newly diagnosed Multiple Myeloma (NDMM) who are eligible for ASCT: Primary Results of the Perseus Trial $GMAB #Genmab $JNJ" [X Link](https://x.com/EgidiusLambrech/status/1726971736716185787) 2023-11-21T14:32Z [---] followers, [---] engagements "Janssen submits Application to the #European Medicines Agency for #RYBREVANT (#amivantamab) + Chemotherapy for the Treatment of Adult Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer After Failure of Prior Therapy $GMAB #Genmab $JNJ #EMA" [X Link](https://x.com/EgidiusLambrech/status/1727963609702060202) 2023-11-24T08:13Z [---] followers, [----] engagements "* FDA grants Breakthrough Therapy Designation * European Medicines Agency (EMA) validates regulatory application for #epcoritamab for R/R Follicular Lymphoma (FL) after two or more lines of systemic therapy #Genmab #AbbVie $GMAB $ABBV EPKINLY/TEPKINLY" [X Link](https://x.com/EgidiusLambrech/status/1729123910481031385) 2023-11-27T13:04Z [---] followers, [---] engagements "#Amivantamab $JNJ $GMAB #Genmab The addition of amivantamab to chemotherapy in patients with advanced nonsmall-cell lung cancer with EGFR exon [--] insertions resulted in significantly longer progression-free survival. Full results of the PAPILLON trial: https://t.co/wEeOGpV5Wu #Oncology The addition of amivantamab to chemotherapy in patients with advanced nonsmall-cell lung cancer with EGFR exon [--] insertions resulted in significantly longer progression-free survival. Full results of the PAPILLON trial: https://t.co/wEeOGpV5Wu #Oncology" [X Link](https://x.com/EgidiusLambrech/status/1730135001230942609) 2023-11-30T08:01Z [---] followers, [----] engagements "#Tisotumab Vedotin Survival Data in #Cervical Cancer Are Game-Changing Treatment with #Tivdak may be a standard of care in second- or third-line recurrent or metastatic cervical cancer says Brian Slomovitz MD $GMAB $SGEN $PFE Genmab Seagen Pfizer https://www.cancernetwork.com/view/tisotumab-vedotin-survival-data-in-cervical-cancer-are-game-changing- https://www.cancernetwork.com/view/tisotumab-vedotin-survival-data-in-cervical-cancer-are-game-changing-" [X Link](https://x.com/EgidiusLambrech/status/1730191271371649506) 2023-11-30T11:45Z [---] followers, [---] engagements "#Genmab reports promising results for elusive lymphoma candidate #Epcoritamab $GMAB $ABBV #AbbVie #ASH23" [X Link](https://x.com/EgidiusLambrech/status/1734120137668595991) 2023-12-11T07:57Z [---] followers, [---] engagements "Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen #Tivdak #Tisotumab Vedotin $GMAB #Genmab $SGEN $PFE https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-all-required-regulatory-approvals-complete https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-all-required-regulatory-approvals-complete" [X Link](https://x.com/EgidiusLambrech/status/1734554915874144351) 2023-12-12T12:44Z [---] followers, [---] engagements "Behandeling multipel myeloom aangevuld met de antistof #daratumumab $JNJ $GMAB #Genmab #Darzalex" [X Link](https://x.com/EgidiusLambrech/status/1735607547732586830) 2023-12-15T10:27Z [---] followers, [---] engagements "First line #amivantamab submission filed: $JNJ submits sBLA and New Drug Application to U.S. FDA seeking Approval of #RYBREVANT Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) / MARIPOSA $GMAB #Genmab" [X Link](https://x.com/EgidiusLambrech/status/1737860129142546864) 2023-12-21T15:38Z [---] followers, [---] engagements "and the #amivantamab MARIPOSA EMA filing; impressive $JNJ $GMAB #Genmab" [X Link](https://x.com/EgidiusLambrech/status/1737863933409579183) 2023-12-21T15:53Z [---] followers, [---] engagements "New Ph3 trial 1st line Subcutaneous #Epcoritamab in combination with Intravenous Rituximab and Oral Lenalidomide (R2) -Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) #Genmab #AbbVie $GMAB $ABBV EPKINLY/TEPKINLY" [X Link](https://x.com/EgidiusLambrech/status/1743281098803536015) 2024-01-05T14:39Z [---] followers, [---] engagements "$JNJ $GMAB #Genmab "Duato noted that J&Js [----] sales projection for new multiple myeloma entrant #Tecvayli is 25% higher than Wall Streets estimate for the same year. For another bispecific #Talvey J&Js expected sales figure in [----] doubles analyst expectations" JPM24: Johnson & Johnson CEO says Tecvayli Talvey and several other meds are set to trounce analyst estimates https://t.co/A976oB1n4y JPM24: Johnson & Johnson CEO says Tecvayli Talvey and several other meds are set to trounce analyst estimates https://t.co/A976oB1n4y" [X Link](https://x.com/EgidiusLambrech/status/1744646917173232036) 2024-01-09T09:06Z [---] followers, [----] engagements "Interview with Tahi Ahmadi Chief Medical Officer at #Genmab and Jacqueline Nielsen Therapeutic Area Head for Hematology at #AbbVie on #epcoritamab for patients with relapsed/refractory Follicular Lymphoma $GMAB $ABBV #Epkinly #Tepkinly" [X Link](https://x.com/EgidiusLambrech/status/1747618680739954826) 2024-01-17T13:55Z [---] followers, [---] engagements "#Epkinly approved in brazil #Epcoritamab #Genmab #AbbVie $GMAB $ABBV ANVISA aprova EPKINLY (epcoritamabe) primeiro anticorpo biespecfico (DuoBody-CD3xCD20) para tratamento de linfoma difuso de grandes clulas B recidivo ou refratrio" [X Link](https://x.com/EgidiusLambrech/status/1752274568616501533) 2024-01-30T10:16Z [---] followers, [---] engagements "UK NICE #Epcoritamab #Tepkinly #Genmab #AbbVie $GMAB $ABBV NICE Recommends Subcutaneous Treatment Option Tepkinly (epcoritamab) for Eligible*Adults with Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy https://t.co/s9AjFcflzo NICE Recommends Subcutaneous Treatment Option Tepkinly (epcoritamab) for Eligible*Adults with Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy https://t.co/s9AjFcflzo" [X Link](https://x.com/EgidiusLambrech/status/1752983602315350220) 2024-02-01T09:13Z [---] followers, [----] engagements "$JNJ Submits Extension to the European Medicines Agency Seeking Approval of #RYBREVANT (amivantamab) in combination with Lazertinib for the #First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer #Genmab $GMAB #MARIPOSA #EMA" [X Link](https://x.com/EgidiusLambrech/status/1755683797897453659) 2024-02-08T20:03Z [---] followers, [---] engagements "#Tisotumab Vedotin (Tissue Factor ADC) Planned China submissions [----] - Zai Lab to submit an NDA to the NMPA in second-line+ cervical cancer. $GMAB $PFE #Genmab #Pfizer #Tivdak https://www.businesswire.com/news/home/20240227802106/en/Zai-Lab-Announces-Full-Year-2023-Financial-Results-and-Recent-Corporate-Updates https://www.businesswire.com/news/home/20240227802106/en/Zai-Lab-Announces-Full-Year-2023-Financial-Results-and-Recent-Corporate-Updates" [X Link](https://x.com/EgidiusLambrech/status/1762860345570275339) 2024-02-28T15:20Z [---] followers, [---] engagements "$GMAB $ABBV #Genmab #AbbVie #epcoritamab #Tepkinly NICE UK People with a type of lymphoma can be offered a new treatment option to fight a type of abnormal white blood cell that builds up in the lymph nodes or other organs. Epcoritamab is recommended for use in the NHS in England. Learn more: https://t.co/mskqyH4O6i #NICENews https://t.co/cRHw7hntMP People with a type of lymphoma can be offered a new treatment option to fight a type of abnormal white blood cell that builds up in the lymph nodes or other organs. Epcoritamab is recommended for use in the NHS in England. Learn more:" [X Link](https://x.com/EgidiusLambrech/status/1765356811484377131) 2024-03-06T12:40Z [---] followers, [---] engagements "Johnson & Johnson submits application to the European Medicines Agency for #DARZALEX (daratumumab)-based #quadruplet therapy for the treatment of patients with transplant-eligible #newly diagnosed multiple myeloma #PERSEUS #EMA $JNJ $GMAB #Genmab" [X Link](https://x.com/EgidiusLambrech/status/1765377397396828631) 2024-03-06T14:02Z [---] followers, [---] engagements "#Epcoritamab a Promising Therapy for #Richter Syndrome $GMAB $JNJ #Genmab #AbbVie #Tepkinly" [X Link](https://x.com/EgidiusLambrech/status/1765699154313888175) 2024-03-07T11:20Z [---] followers, [---] engagements "#Genmab said on March [--] that it has filed its bispecific antibody #Epkinly (#epcoritamab) being codeveloped with #AbbVie for an additional indication of relapsed or refractory follicular #lymphoma (Grade 1-3A) in #Japan. $GMAB $ABBV https://pj.jiho.jp/article/250573 https://pj.jiho.jp/article/250573" [X Link](https://x.com/EgidiusLambrech/status/1767525126705180815) 2024-03-12T12:16Z [---] followers, [---] engagements "Darzalex $JNJ $GMAB #Genmab UPDATE: US FDA Priority Review received for Phase [--] PERSEUS submission UPDATE: US FDA Priority Review received for Phase [--] PERSEUS submission" [X Link](https://x.com/EgidiusLambrech/status/1772728896695238712) 2024-03-26T20:54Z [---] followers, [----] engagements "@BertrandBio OTHER ONCOLOGY this quarter only Talvey and Rybrevant then I guess or can you think of anything else in there $178mn $JNJ $GMAB" [X Link](https://x.com/EgidiusLambrech/status/1780216034173104266) 2024-04-16T12:45Z [---] followers, [---] engagements "US FDA mandates label updates on CAR-T cancer therapies "participants receiving treatment with these products should be monitored life-long for secondary malignancies" $JNJ Carvykti $NVS Kymriah $GILD Yescarta $GMAB via @YahooFinance https://finance.yahoo.com/news/us-fda-mandates-label-updates-223309187.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr https://finance.yahoo.com/news/us-fda-mandates-label-updates-223309187.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr" [X Link](https://x.com/EgidiusLambrech/status/1781291641623441500) 2024-04-19T11:59Z [---] followers, [---] engagements "#Rybrevant - positive opinion on variation to marketing authorisation European Medicines Agency PAPILLON- with carboplatin and pemetrexed for the firstline treatment of advanced NSCLC with activating EGFR Exon20 $JNJ $GMAB #Genmab #Amivantamab #EMA https://www.ema.europa.eu/en/medicines/human/variation/rybrevant https://www.ema.europa.eu/en/medicines/human/variation/rybrevant" [X Link](https://x.com/EgidiusLambrech/status/1783838583952216451) 2024-04-26T12:40Z [---] followers, [---] engagements "AMGEN TO SUBMIT #TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY #EMA $AMGN $GMAB #Genmab #Tepezza https://prn.to/3w6VCZh https://prn.to/3w6VCZh" [X Link](https://x.com/EgidiusLambrech/status/1783853359574708668) 2024-04-26T13:39Z [---] followers, [---] engagements "#NovoNordisk: Mim8 demonstrates superior reduction of treated bleeding episodes -haemophilia A $NVO #Mim8 is a bispecific antibody created under a collaboration between #Genmab and Novo Nordisk using $GMAB s DuoBody technology. #Royalties #Milestones https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.htmlid=168515 https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.htmlid=168515" [X Link](https://x.com/EgidiusLambrech/status/1790076985160425572) 2024-05-13T17:49Z [---] followers, [---] engagements "@DrJulieVose discusses her upcoming ASCO presentation on #epcoritamab in R/R follicular lymphoma. #lymsm #ASCO24 $GMAB $ABBV #Genmab #AbbVie .@DrJulieVose discusses her upcoming @ASCO presentation on epcoritamab in R/R follicular lymphoma. #lymsm #ASCO24 To view our full conference coverage visit: https://t.co/1sfycf2uq1 https://t.co/wpegGZEb0g .@DrJulieVose discusses her upcoming @ASCO presentation on epcoritamab in R/R follicular lymphoma. #lymsm #ASCO24 To view our full conference coverage visit: https://t.co/1sfycf2uq1 https://t.co/wpegGZEb0g" [X Link](https://x.com/EgidiusLambrech/status/1796136990078816632) 2024-05-30T11:10Z [---] followers, [---] engagements "#Tisotumab vedotin #Tivdak #Genmab #Pfizer $GMAB $PFE Recurrent cervical cancer has a poor prognosis. The median overall survival was nearly [--] year with tisotumab vedotin an antibodydrug conjugate as compared with [---] months with chemotherapy. Read the full trial results: https://t.co/WasnIRU8Dm https://t.co/Z6Q1y6VrXX Recurrent cervical cancer has a poor prognosis. The median overall survival was nearly [--] year with tisotumab vedotin an antibodydrug conjugate as compared with [---] months with chemotherapy. Read the full trial results: https://t.co/WasnIRU8Dm https://t.co/Z6Q1y6VrXX" [X Link](https://x.com/EgidiusLambrech/status/1808779918471233666) 2024-07-04T08:28Z [---] followers, [---] engagements "#TIVDAK (tisotumab vedotin-tftv) Mechanism of Action Cervical cancer ADC #Genmab #Pfizer $GMAB $PFE https://www.youtube.com/watchv=R1WxeM4751c https://www.youtube.com/watchv=R1WxeM4751c" [X Link](https://x.com/EgidiusLambrech/status/1811702354183331946) 2024-07-12T10:01Z [---] followers, [---] engagements "Bispecific antibody #Epkinly shows miraculous results in 3rd-line treatment of DLBCL' #Genmab #AbbVie $GMAB $ABBV #Epcoritamab https://www.koreabiomed.com/news/articleView.htmlidxno=24545 https://www.koreabiomed.com/news/articleView.htmlidxno=24545" [X Link](https://x.com/EgidiusLambrech/status/1812755668182393194) 2024-07-15T07:46Z [---] followers, [----] engagements "#Tivdak (Tisotumab Vedotin) Cervical cancer ADC #Genmab #Pfizer $GMAB $PFE Tivdak (Tisotumab Vedotin) for Recurrent Cervical Cancer Recurrent cervical cancer is a life-threatening disease with limited treatment options available when disease progression occurs after first-line combination therapy. For patients with recurrent cervical cancer limited https://t.co/oOzMi95jkY Tivdak (Tisotumab Vedotin) for Recurrent Cervical Cancer Recurrent cervical cancer is a life-threatening disease with limited treatment options available when disease progression occurs after first-line combination therapy." [X Link](https://x.com/EgidiusLambrech/status/1812837148006965530) 2024-07-15T13:10Z [---] followers, [----] engagements "New trial: SC Injected #Epcoritamab + Lenalidomide Tablets Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) #Genmab #AbbVie $GMAB $ABBV #Epkinly https://www.clinicaltrials.gov/study/NCT06508658 https://www.clinicaltrials.gov/study/NCT06508658" [X Link](https://x.com/EgidiusLambrech/status/1813928186121699709) 2024-07-18T13:25Z [---] followers, [---] engagements "#Epcoritamab vs SoC (SCHOLAR-5 cohort) in patients with R/R FL #Genmab #AbbVie $GMAB $ABBV #Epkinly via @YouTube https://youtu.be/SQgjUgIJU4Efeature=shared https://youtu.be/SQgjUgIJU4Efeature=shared" [X Link](https://x.com/EgidiusLambrech/status/1815646691556507774) 2024-07-23T07:14Z [---] followers, [---] engagements "#AbbVie's #EPKINLY Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency #Genmab $ABBV $GMAB #Epcoritamab https://prn.to/46d212J https://prn.to/46d212J" [X Link](https://x.com/EgidiusLambrech/status/1815708356276887630) 2024-07-23T11:19Z [---] followers, [---] engagements "#EMA CHMP recommends #RYBREVANT (#amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy $JNJ $GMAB #Genmab https://www.globenewswire.com/en/news-release/2024/07/26/2919538/0/en/CHMP-recommends-RYBREVANT-amivantamab-in-combination-with-chemotherapy-for-the-treatment-of-adult-patients-with-advanced-EGFR-mutated-non-small-cell-lung-cancer-NSCLC-after-failure.html" [X Link](https://x.com/EgidiusLambrech/status/1816820078408507750) 2024-07-26T12:57Z [---] followers, [---] engagements "#DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible - PERSEUS $JNJ $GMAB #Genmab https://www.jnj.com/media-center/press-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-regimen-approved-in-the-u-s-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible" [X Link](https://x.com/EgidiusLambrech/status/1818623053586370615) 2024-07-31T12:21Z [---] followers, [---] engagements "Amgen's marketing efforts help boost #Tepezza sales #Teprotumumab $AMGN $GMAB #Genmab #Royalties https://www.fiercepharma.com/pharma/amgens-marketing-efforts-help-boost-tepezza-sales https://www.fiercepharma.com/pharma/amgens-marketing-efforts-help-boost-tepezza-sales" [X Link](https://x.com/EgidiusLambrech/status/1821434403966357922) 2024-08-08T06:32Z [---] followers, [----] engagements "#Epcoritamab Optimization Lowers Neurotoxicity Boosts Outpatient Feasibility in Follicular Lymphoma $GMAB $ABBV #Genmab #AbbVie #Epkinly via @onclive https://www.onclive.com/view/epcoritamab-optimization-lowers-neurotoxicity-boosts-outpatient-feasibility-in-follicular-lymphoma https://www.onclive.com/view/epcoritamab-optimization-lowers-neurotoxicity-boosts-outpatient-feasibility-in-follicular-lymphoma" [X Link](https://x.com/EgidiusLambrech/status/1821443758614888692) 2024-08-08T07:10Z [---] followers, [----] engagements "Comparisons of treatment outcomes of #epcoritamab versus chemoimmunotherapy polatuzumab-based regimens tafasitamab-based regimens or CAR T-cell therapy in 3rd-line or later relapsed/refractory large B-cell lymphoma $GMAB $ABBV #Genmab #AbbVie #Epkinly https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01594-x#citeas https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01594-x#citeas" [X Link](https://x.com/EgidiusLambrech/status/1825423760607908257) 2024-08-19T06:45Z [---] followers, [----] engagements "#RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. $JNJ $GMAB #Genmab #Royalties https://prn.to/3YToY9y https://prn.to/3YToY9y" [X Link](https://x.com/EgidiusLambrech/status/1825856708213690441) 2024-08-20T11:25Z [---] followers, [---] engagements "FDA Approval Alert: #Epcoritamab in Relapsed/Refractory Follicular Lymphoma $GMAB $ABBV #Genmab #AbbVie #Epkinly via @@CancerNetwrk https://www.cancernetwork.com/view/fda-approval-alert-epcoritamab-in-relapsed-refractory-follicular-lymphoma https://www.cancernetwork.com/view/fda-approval-alert-epcoritamab-in-relapsed-refractory-follicular-lymphoma" [X Link](https://x.com/EgidiusLambrech/status/1826971560931955045) 2024-08-23T13:15Z [---] followers, [----] engagements "$GMAB $ABBV #Genmab #AbbVie #Epcoritamab #Epkinly CONGRESS POSTER #SOHO2024 Yasmin Karimi @Yhkarimi presents extended follow-up data beyond [---] years from the pivotal expansion cohort of the phase II EPCORE NHL-1 study of epcoritamab monotherapy in R/R #DLBCL (N=157). Of pts with a CR (n=65) 54% remained in CR at [--] https://t.co/mkTvkPIput CONGRESS POSTER #SOHO2024 Yasmin Karimi @Yhkarimi presents extended follow-up data beyond [---] years from the pivotal expansion cohort of the phase II EPCORE NHL-1 study of epcoritamab monotherapy in R/R #DLBCL (N=157). Of pts with a CR (n=65) 54% remained" [X Link](https://x.com/EgidiusLambrech/status/1831310139934081404) 2024-09-04T12:35Z [---] followers, [---] engagements "#ESMO24: #Genmab Has AbbVie In Its Sights As Rina-S Shines In Ovarian Cancer - $GMAB Rinatabart Sesutecan http://scrip.citeline.com/articles/2024/09/16/esmo-24-genmab-has-abbvie-in-its-sights-as-rina-s-shines-in-ovarian-cancer http://scrip.citeline.com/articles/2024/09/16/esmo-24-genmab-has-abbvie-in-its-sights-as-rina-s-shines-in-ovarian-cancer" [X Link](https://x.com/EgidiusLambrech/status/1835955699274133833) 2024-09-17T08:15Z [---] followers, [---] engagements "$GMAB $ABBV #Genmab #AbbVie #Epcoritamab #Epkinly In this episode of #OncLiveOnAir @JenCrombieMD of @DanaFarber shares insights about the @US_FDA approval of epcoritamab for patients with relapsed/refractory follicular #lymphoma. #lymsm #oncology https://t.co/b0H9YnBeYu https://t.co/PKQrMyGQL3 In this episode of #OncLiveOnAir @JenCrombieMD of @DanaFarber shares insights about the @US_FDA approval of epcoritamab for patients with relapsed/refractory follicular #lymphoma. #lymsm #oncology https://t.co/b0H9YnBeYu https://t.co/PKQrMyGQL3" [X Link](https://x.com/EgidiusLambrech/status/1836008952578125843) 2024-09-17T11:47Z [---] followers, [----] engagements "New #Novartis data in relapsing MS reinforce benefits of #Kesimpta for first-line and switch patients $NVS $GMAB #Genmab https://www.novartis.com/news/media-releases/new-novartis-data-relapsing-ms-reinforce-benefits-kesimpta-first-line-and-switch-patients https://www.novartis.com/news/media-releases/new-novartis-data-relapsing-ms-reinforce-benefits-kesimpta-first-line-and-switch-patients" [X Link](https://x.com/EgidiusLambrech/status/1836312627158335580) 2024-09-18T07:53Z [---] followers, [---] engagements "#RYBREVANT (#amivantamab-vmjw) plus standard of care #approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer $JNJ $GMAB #Genmab #Royalties https://prn.to/3XQ5otI https://prn.to/3XQ5otI" [X Link](https://x.com/EgidiusLambrech/status/1837020415316705513) 2024-09-20T06:46Z [---] followers, [---] engagements "#Tepezza (Teprotumumab) Receives Approval in #Japan for the Treatment of Active Thyroid Eye Disease $AMGN #Genmab $GMAB #Royalties https://prn.to/4efprYf https://prn.to/4efprYf" [X Link](https://x.com/EgidiusLambrech/status/1838827473460506758) 2024-09-25T06:26Z [---] followers, [---] engagements "$JNJ $GMAB #Genmab #Darzalex #Daratumumab CONGRESS #IMS2024 PRESENTATION Jill Corre shares an MRD update from the phase III CASSIOPEIA trial (N = 1085) which established D-VTd as a standard of care for transplant eligible NDMM. Extended follow-up demonstrated that DARA-based induction/consolidation and maintenance https://t.co/7tfJIewuYY CONGRESS #IMS2024 PRESENTATION Jill Corre shares an MRD update from the phase III CASSIOPEIA trial (N = 1085) which established D-VTd as a standard of care for transplant eligible NDMM. Extended follow-up demonstrated that DARA-based induction/consolidation" [X Link](https://x.com/EgidiusLambrech/status/1839256195695055105) 2024-09-26T10:50Z [---] followers, [----] engagements "$JNJ $GMAB #Genmab #Darzalex #Daratumumab CONGRESS #IMS2024 PRESENTATION Meletios Dimopoulos @thanosdimop shares findings from a cytogenetic risk analysis of the phase III PERSEUS trial (N = 709) which demonstrated a significant PFS benefit for the addition of daratumumab (D) to VRd induction and consolidation https://t.co/42G8mmVmPt CONGRESS #IMS2024 PRESENTATION Meletios Dimopoulos @thanosdimop shares findings from a cytogenetic risk analysis of the phase III PERSEUS trial (N = 709) which demonstrated a significant PFS benefit for the addition of daratumumab (D) to VRd induction and" [X Link](https://x.com/EgidiusLambrech/status/1839273533387440279) 2024-09-26T11:59Z [---] followers, [----] engagements "#Epcoritamab in R/R large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial 'deep responses across subgroups including patients with hard-to-treat disease and expected poor prognosis' #Genmab $GMAB #AbbVie $ABBV #Epkinly https://www.nature.com/articles/s41375-024-02410-8 https://www.nature.com/articles/s41375-024-02410-8" [X Link](https://x.com/EgidiusLambrech/status/1839631068636344406) 2024-09-27T11:40Z [---] followers, [---] engagements "Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on #Tisotumab Vedotin state of art - Therapeutic Advances in Medical Oncology #Tivdak $GMAB $PFE #Genmab #Pfizer https://journals.sagepub.com/doi/10.1177/17588359241277647 https://journals.sagepub.com/doi/10.1177/17588359241277647" [X Link](https://x.com/EgidiusLambrech/status/1840715720197284040) 2024-09-30T11:30Z [---] followers, [---] engagements "Johnson & Johnson files for U.S. FDA approval of #DARZALEX FASPRO-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned #CEPHEUS $JNJ $GMAB #genmab https://prn.to/3Bu49aX https://prn.to/3Bu49aX" [X Link](https://x.com/EgidiusLambrech/status/1841008360612643139) 2024-10-01T06:52Z [---] followers, [---] engagements "🎧 Listen to Dr Ignace Vergote discuss: #Tisotumab Vedotin in Second- & Third-Line Recurrent CervicalCancer #Genmab #Pfizer $GMAB $PFE #Tivdak #WeeklyPodcast 🎧 Listen to Dr Ignace Vergote discuss #Tisotumab Vidotin in Second- & Third-Line #Recurrent #CervicalCancer @ https://t.co/BxuLB6RB9L @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 https://t.co/z59mvKdglG #WeeklyPodcast 🎧 Listen to Dr Ignace Vergote discuss #Tisotumab Vidotin in Second- & Third-Line #Recurrent #CervicalCancer @ https://t.co/BxuLB6RB9L" [X Link](https://x.com/EgidiusLambrech/status/1843916105355800611) 2024-10-09T07:27Z [---] followers, [----] engagements "Hemab is using #Genmab's DuoBody technology. Hemab Therapeutics is actively enrolling a Phase [--] clinical trial of HMB-001 a subcutaneous injection designed to restore clot formation impaired by Glanzmann Thrombasthenia. $GMAB $NOVO For those living with Glanzmann Thrombasthenia (GT) there is no time to wait. Over a century since GT was first described treatment options remain limited. GT is a severe bleeding disorder that limits blood's ability to clot presenting constant challengesfrom frequent https://t.co/ca5ta5LFGM For those living with Glanzmann Thrombasthenia (GT) there is no time to" [X Link](https://x.com/EgidiusLambrech/status/1843980257872978351) 2024-10-09T11:42Z [---] followers, [----] engagements "Johnson & Johnson submits application to the European Medicines Agency for DARZALEX (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patients #EMA D-VRd CEPHEUS $JNJ $GMAB #Genmab https://www.globenewswire.com/news-release/2024/10/10/2961071/0/en/Johnson-Johnson-submits-application-to-the-European-Medicines-Agency-for-DARZALEX-daratumumab-SC-based-quadruplet-regimen-for-newly-diagnosed-multiple-myeloma-patients.html" [X Link](https://x.com/EgidiusLambrech/status/1844315781586354602) 2024-10-10T09:55Z [---] followers, [---] engagements "Patients thrown lifeline after NICE lifts restrictions on game-changing treatment #Teclistamab $JNJ $GMAB #Genmab #Tecvayli https://www.myeloma.org.uk/news/patients-thrown-lifeline-after-nice-lifts-restrictions-on-game-changing-treatment/ https://www.myeloma.org.uk/news/patients-thrown-lifeline-after-nice-lifts-restrictions-on-game-changing-treatment/" [X Link](https://x.com/EgidiusLambrech/status/1844627149451338115) 2024-10-11T06:32Z [---] followers, [---] engagements "#DARZALEX (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible #PERSEUS #EMA $JNJ $GMAB #Genmab https://www.globenewswire.com/news-release/2024/10/23/2967491/0/en/DARZALEX-daratumumab-SC-based-quadruplet-regimen-approved-by-the-European-Commission-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible.html" [X Link](https://x.com/EgidiusLambrech/status/1849009441095491926) 2024-10-23T08:46Z [---] followers, [---] engagements "#Tisotumab Vedotin vs Chemo in Japanese Patients With R/M Cervical Cancer -innovaTV [---] #JSCO2024 During the median follow-up period of [----] months the median OS was 15.0m in the TV group vs 8.5m in the chemotherapy group #Tivdak #Genmab $GMAB $PFE https://medical.nikkeibp.co.jp/leaf/all/cancernavi/news/202410/586322.html https://medical.nikkeibp.co.jp/leaf/all/cancernavi/news/202410/586322.html" [X Link](https://x.com/EgidiusLambrech/status/1851620513489072402) 2024-10-30T13:41Z [---] followers, [---] engagements "last years ESMO data showed median OS [----] mo vs [---] mo (after median survival follow-up [----] mo) so is the improvement only in Japanese patients or does it have anything to do with improved toxicity management #Genmab $GMAB $PFE #Pfizer https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/innovatv-301-engot-cx12-gog-3057-a-global-randomized-open-label-phase-iii-study-of-tisotumab-vedotin-vs-investigator-s-choice-of-chemotherapy-i" [X Link](https://x.com/EgidiusLambrech/status/1851624322965676036) 2024-10-30T13:56Z [---] followers, [---] engagements "@IJGConline the Japanese Society of Clinical Oncology meeting shows much better data Any explanation During the median follow-up of [----] months median OS was 15.0mo in the #Tisotumab Vedotin group vs 8.5mo in the chemo group (was [----] vs 9.5) $GMAB $PFE @Genmab https://medical.nikkeibp.co.jp/leaf/all/cancernavi/news/202410/586322.html https://medical.nikkeibp.co.jp/leaf/all/cancernavi/news/202410/586322.html" [X Link](https://x.com/EgidiusLambrech/status/1851966572165804530) 2024-10-31T12:36Z [---] followers, [---] engagements "Drugs for unmet needs and those from experienced companies had the best chance for successful launches in [----] '#Genmab and #AbbVies debut of #Epkinly for patients with DLBCL has also exceeded expectations in its battle with Roche's Columvi.' https://www.fiercepharma.com/pharma/drugs-unmet-needs-and-those-experienced-companies-have-best-chance-successful-launches https://www.fiercepharma.com/pharma/drugs-unmet-needs-and-those-experienced-companies-have-best-chance-successful-launches" [X Link](https://x.com/EgidiusLambrech/status/1854496252068504014) 2024-11-07T12:08Z [---] followers, [---] engagements "CHMP adopted a positive opinion on the marketing authorisation for #Rybrevant. #EMA (MARIPOSA) $JNJ $GMAB #Genmab #amivantamab" [X Link](https://x.com/EgidiusLambrech/status/1857443240070242471) 2024-11-15T15:19Z [---] followers, [---] engagements "@Chris_Whittall and wouldn't the increased use of margin agreements in the swap markets also be a factor as it mitigates the counterparty risk and thus credit spread" [X Link](https://x.com/EgidiusLambrech/status/1858454992350319076) 2024-11-18T10:19Z [---] followers, [--] engagements "Teprotumumab / Tepezza $AMGN $GMAB #Amgen #Genmab The FDA approved Tepezza in [----] for treating TED following promising results from clinical trials. The results of [--] recent real-world studies show encouraging outcomes and indicate that the drug is performing well for a high percentage of patients https://t.co/8AAs8vwn9g https://t.co/WAFLmmuj3o The FDA approved Tepezza in [----] for treating TED following promising results from clinical trials. The results of [--] recent real-world studies show encouraging outcomes and indicate that the drug is performing well for a high percentage of patients" [X Link](https://x.com/EgidiusLambrech/status/1858510693387108548) 2024-11-18T14:00Z [---] followers, [----] engagements "Novartis upgrades #Kesimpta peak sales estimates to $6bn $NOVN $NVS $GMAB #Genmab #Royalties #ofatumumab" [X Link](https://x.com/EgidiusLambrech/status/1859559849484288132) 2024-11-21T11:29Z [---] followers, [----] engagements "@BertrandBio Ipsen sold one for $158m last summer and I think AbbVie once bought one for $350m many years ago. Deflation 😁Don't tell Trump he'll claim it as his success 😆 It seems the Pediatric PRV's are worth more" [X Link](https://x.com/EgidiusLambrech/status/1861750254476878069) 2024-11-27T12:33Z [---] followers, [--] engagements "the addition of #daratumumab (darzalex) to VRd significantly increased MRD negativity rates compared to VRd alone in transplant-ineligible patients $JNJ $GMAB #Genmab via @@Pharmacy_Times https://www.pharmacytimes.com/view/ash-2024-expert-highlights-bolstered-mrd-negativity-with-daratumumab-vrd-in-multiple-myeloma https://www.pharmacytimes.com/view/ash-2024-expert-highlights-bolstered-mrd-negativity-with-daratumumab-vrd-in-multiple-myeloma" [X Link](https://x.com/EgidiusLambrech/status/1866870680081338720) 2024-12-11T15:40Z [---] followers, [---] engagements "#Genmab #AbbVie $GMAB $ABBV #Epcoritamab #Epkinly #CLL Promising results for heavily pretreated #CLL #Epcoritamab achieved 39% complete response & 75% uMRD in the EPCORE CLL-1 trial. Optimized dosing reduced severe CRS & #Neurotoxicity. https://t.co/iLCq9IZYuq #CLLSM #Hematology #ASH24 @DanilovLab Promising results for heavily pretreated #CLL #Epcoritamab achieved 39% complete response & 75% uMRD in the EPCORE CLL-1 trial. Optimized dosing reduced severe CRS & #Neurotoxicity. https://t.co/iLCq9IZYuq #CLLSM #Hematology #ASH24 @DanilovLab" [X Link](https://x.com/EgidiusLambrech/status/1867142695283822667) 2024-12-12T09:41Z [---] followers, [----] engagements "Essential material for both @Genmab and #AbbVie investors [----] R&D Update and ASH Data Review webcast replay and supporting presentations via: $GMAB $ABBV $ROG $RHHBY #Epkinly #Epcoritamab #Rina-S https://ir.genmab.com/events-presentations https://ir.genmab.com/events-presentations" [X Link](https://x.com/EgidiusLambrech/status/1867563241653907562) 2024-12-13T13:32Z [---] followers, [---] engagements "@amandagarces @statnews @angRchen it's not just AbbVie it's 50/50 partnered with Genmab" [X Link](https://x.com/EgidiusLambrech/status/1867585163108266279) 2024-12-13T14:59Z [---] followers, [---] engagements "Tivdak officially launched in Hong Kong and Macao #Tisotumab Vedotin $GMAB #Genmab $PFE #Pfizer #Zailab https://finance.china.com.cn/industry/medicine/20241216/6197105.shtml https://finance.china.com.cn/industry/medicine/20241216/6197105.shtml" [X Link](https://x.com/EgidiusLambrech/status/1868665260443680897) 2024-12-16T14:31Z [---] followers, [---] engagements "#Kempen raises target price for #Genmab to DKK [----] (2650) reiterates #Buy $GMAB BN #MarketScreener https://www.marketscreener.com/quote/stock/GENMAB-A-S-63733191/news/Kempen-raises-target-price-for-Genmab-to-DKK-2-950-2-650-reiterates-Buy-BN-48616994/utm_source=twitter&utm_medium=social&utm_campaign=share https://www.marketscreener.com/quote/stock/GENMAB-A-S-63733191/news/Kempen-raises-target-price-for-Genmab-to-DKK-2-950-2-650-reiterates-Buy-BN-48616994/utm_source=twitter&utm_medium=social&utm_campaign=share" [X Link](https://x.com/EgidiusLambrech/status/1869676682610970805) 2024-12-19T09:30Z [---] followers, [---] engagements "European Commission approves #RYBREVANT (#amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer - MARIPOSA $JNJ $GMAB #Genmab #EMA https://www.globenewswire.com/news-release/2024/12/30/3002463/0/en/European-Commission-approves-RYBREVANT-amivantamab-in-combination-with-LAZCLUZE-lazertinib-for-the-first-line-treatment-of-patients-with-EGFR-mutated-advanced-non-small-cell-lung-c.html" [X Link](https://x.com/EgidiusLambrech/status/1873654364709249114) 2024-12-30T08:56Z [---] followers, [----] engagements "@PCM_bio @LuciusJameson @john_bresnahan JNJ is currently reviewing a possible follow up to Darzalex; Hexabody-CD38 or Erzotabart is also developed by Genmab. Decision to opt-in to this 'SuperDara' or not is anticipated somewhere before the end of March" [X Link](https://x.com/EgidiusLambrech/status/1876317214347059664) 2025-01-06T17:17Z [---] followers, [---] engagements "#Rybrevant $JNJ $GMAB #Genmab Amivantamab #BREAKING: Topline results for the key secondary endpoint of overall survival from the Phase [--] MARIPOSA study highlight treatment progress for patients with EGFR-mutated #NSCLC: https://t.co/l3tpGs7VJT #JNJOncology https://t.co/5nP7vLEADm #BREAKING: Topline results for the key secondary endpoint of overall survival from the Phase [--] MARIPOSA study highlight treatment progress for patients with EGFR-mutated #NSCLC: https://t.co/l3tpGs7VJT #JNJOncology https://t.co/5nP7vLEADm" [X Link](https://x.com/EgidiusLambrech/status/1876627808094752843) 2025-01-07T13:51Z [---] followers, [----] engagements "$GMAB $ABBV #Genmab #AbbVie #Epcoritamab #Epkinly #Hematology Impressive results of #epcoritamab + GEMOX in transplant ineligible R/R DLBCL patients with ORR/CR 85%/61% and even better if given in 2L with ORR/CR 90/74% #lymsm https://t.co/ZoVaYCUaDz #Hematology Impressive results of #epcoritamab + GEMOX in transplant ineligible R/R DLBCL patients with ORR/CR 85%/61% and even better if given in 2L with ORR/CR 90/74% #lymsm https://t.co/ZoVaYCUaDz" [X Link](https://x.com/EgidiusLambrech/status/1878741477649682759) 2025-01-13T09:50Z [---] followers, [----] engagements "European Commission approves LAZCLUZE (lazertinib) in combination with #RYBREVANT (#amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer $JNJ $GMAB #Genmab #EMA #NSCLC https://finance.yahoo.com/news/european-commission-approves-lazcluze-lazertinib-083000278.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr https://finance.yahoo.com/news/european-commission-approves-lazcluze-lazertinib-083000278.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr" [X Link](https://x.com/EgidiusLambrech/status/1881641463416820204) 2025-01-21T09:54Z [---] followers, [----] engagements "@Mylovanov [--------] lives not even close even when you include Spain which apparently is now part of BRICS 😂" [X Link](https://x.com/EgidiusLambrech/status/1882105473471844729) 2025-01-22T16:38Z [---] followers, [---] engagements "'Enhancing complement activation by therapeutic anti-tumor antibodies' Focus on hexamerization & publication date March [----]. What other Hexabody news in March [--] could this be aligned with🤔😄 #Hexabody-CD38 #Erzotabart @Genmab $GMAB $JNJ #SuperDara https://www.sciencedirect.com/science/article/pii/S1044532324000605 https://www.sciencedirect.com/science/article/pii/S1044532324000605" [X Link](https://x.com/EgidiusLambrech/status/1884546122695295037) 2025-01-29T10:16Z [---] followers, [---] engagements "BMO Capital maintained #Genmab A/S ( $GMAB ) coverage with #Outperform and target $47 Past Target Price: $48" [X Link](https://x.com/EgidiusLambrech/status/1884602454450311670) 2025-01-29T14:00Z [---] followers, [---] engagements "Novartis #Kesimpta Q4 '24 $950mn FY '24 $3224mn (=+49%) #Genmab $GMAB #Ofatumumab #Royalties 10%" [X Link](https://x.com/EgidiusLambrech/status/1885226333728383154) 2025-01-31T07:19Z [---] followers, [---] engagements "#Tivdak(tisotumab vedotin) received a positive opinion from the #CHMP for the treatment of recurrent or metastatic cervical cancer. #Genmab #Pfizer $GMAB $PFE #EMA" [X Link](https://x.com/EgidiusLambrech/status/1885285320922407380) 2025-01-31T11:13Z [---] followers, [---] engagements "#Tisotumab Vedotin Grnes Licht fr neue Option bei Zervixkarzinom #Genmab #Pfizer $GMAB $PFE #Tivdak https://www.pharmazeutische-zeitung.de/gruenes-licht-fuer-neue-option-bei-zervixkarzinom-152890/ https://www.pharmazeutische-zeitung.de/gruenes-licht-fuer-neue-option-bei-zervixkarzinom-152890/" [X Link](https://x.com/EgidiusLambrech/status/1885624561305047133) 2025-02-01T09:41Z [---] followers, [---] engagements "Hemab is using #Genmab's DuoBody technology $GMAB $NOVO NEWS: Today at #EAHAD2025 we presented interim data from the ongoing Phase [--] study of HMB-001 designed to be the first ever prophylactic treatment for Glanzmann thrombasthenia as well as promising HMB-002 preclinical data for Von Willebrand Disease. HIGHLIGHTS: Interim https://t.co/W2tmMS3yRm NEWS: Today at #EAHAD2025 we presented interim data from the ongoing Phase [--] study of HMB-001 designed to be the first ever prophylactic treatment for Glanzmann thrombasthenia as well as promising HMB-002 preclinical data for Von Willebrand Disease." [X Link](https://x.com/EgidiusLambrech/status/1887892639724257667) 2025-02-07T15:54Z [---] followers, [---] engagements "#EPKINLY (epcoritamab) Approved by #Japan Ministry of Health Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory #Follicular Lymphoma $GMAB $ABBV #Genmab #AbbVie https://www.globenewswire.com/news-release/2025/02/20/3029562/0/en/EPKINLY-epcoritamab-Approved-by-Japan-Ministry-of-Health-Labour-and-Welfare-for-Additional-Indication-as-a-Treatment-for-Relapsed-or-Refractory-Follicular-Lymphoma.html" [X Link](https://x.com/EgidiusLambrech/status/1892571470833860831) 2025-02-20T13:46Z [---] followers, [---] engagements "#Genmab reports promising data in ovarian cancer treatment study - Rina-S $GMAB #Rinatabart Sesutecan https://medwatch.com/News/Pharma___Biotech/article18004885.ece https://medwatch.com/News/Pharma___Biotech/article18004885.ece" [X Link](https://x.com/EgidiusLambrech/status/1901902707377496294) 2025-03-18T07:45Z [---] followers, [----] engagements "#SGOMtg [----] Genmabs advantage looks Profound $GMAB Rina-S #Rinatabart Sesutecan https://www.oncologypipeline.com/apexonco/sgo-2025-genmabs-advantage-looks-profound https://www.oncologypipeline.com/apexonco/sgo-2025-genmabs-advantage-looks-profound" [X Link](https://x.com/EgidiusLambrech/status/1902266682472616430) 2025-03-19T07:51Z [---] followers, [---] engagements "#Genmab $GMAB Rina-S #Rinatabart Sesutecan #SGOMtg [----] 6:30 AM on a Saturday in #Rome: Regina Berger Stephan Polterauer & Christian Marth at the Investigator Meeting for the Phase III trial RAINFOL-OV2. 🔬 Testing Rinatabart Sesutecan (Rina-S) for platinum-resistant #OvarianCancer. 💙 #AGOAustria leading as the #ENGOT study group. https://t.co/6cgbOP4zmm 6:30 AM on a Saturday in #Rome: Regina Berger Stephan Polterauer & Christian Marth at the Investigator Meeting for the Phase III trial RAINFOL-OV2. 🔬 Testing Rinatabart Sesutecan (Rina-S) for platinum-resistant #OvarianCancer. 💙" [X Link](https://x.com/EgidiusLambrech/status/1902267166918865290) 2025-03-19T07:53Z [---] followers, [---] engagements "#Genmab Announces Initiation of Share Buy-Back Program $GMAB https://ir.genmab.com/news-releases/news-release-details/genmab-announces-initiation-share-buy-back-program-4 https://ir.genmab.com/news-releases/news-release-details/genmab-announces-initiation-share-buy-back-program-4" [X Link](https://x.com/EgidiusLambrech/status/1904787287226921240) 2025-03-26T06:47Z [---] followers, [---] engagements "#TIVDAK (tisotumab vedotin) Approved by #Japan Ministry of Health Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy Big market for Cervical cancer. $GMAB $PFE #Pfizer https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-japan-ministry-health-labour https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-japan-ministry-health-labour" [X Link](https://x.com/EgidiusLambrech/status/1905233382117683517) 2025-03-27T12:20Z [---] followers, [---] engagements "#TIVDAK (tisotumab vedotin) Approved by #European Commission for Previously Treated Recurrent or Metastatic #Cervical Cancer #Genmab $GMAB #Pfizer $PFE #EMA https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-european-commission https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-european-commission" [X Link](https://x.com/EgidiusLambrech/status/1906759897905037548) 2025-03-31T17:26Z [---] followers, [---] engagements "@fyee0308 @davidmygind $GMAB #Genmab https://www.linkedin.com/posts/mygind-management_biotechanalysis-genmab-precisionmedicine-activity-7311027431589498880-ppKxutm_medium=ios_app&rcm=ACoAAACIYqABSM5yt5vwlKC7IlzfrJTkl7kbQNo&utm_source=social_share_send&utm_campaign=copy_link https://www.linkedin.com/posts/mygind-management_biotechanalysis-genmab-precisionmedicine-activity-7311027431589498880-ppKxutm_medium=ios_app&rcm=ACoAAACIYqABSM5yt5vwlKC7IlzfrJTkl7kbQNo&utm_source=social_share_send&utm_campaign=copy_link" [X Link](https://x.com/EgidiusLambrech/status/1906768170473419234) 2025-03-31T17:58Z [---] followers, [--] engagements "New Chromatography Data Platform Wins Bio-IT World Award for Genmab $GMAB and Genedata "Genmab seeks to integrate AI into everything we do and we are continuously looking for ways that AI can address operational challenges" https://prn.to/4cftzY4 https://prn.to/4cftzY4" [X Link](https://x.com/EgidiusLambrech/status/1908140545332961522) 2025-04-04T12:52Z [---] followers, [---] engagements "European Commission approves #subcutaneous #RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer $JNJ $GMAB #Genmab #EMA https://www.globenewswire.com/news-release/2025/04/07/3056770/0/en/European-Commission-approves-subcutaneous-RYBREVANT-amivantamab-for-the-treatment-of-patients-with-advanced-EGFR-mutated-non-small-cell-lung-cancer.html" [X Link](https://x.com/EgidiusLambrech/status/1909238424034255036) 2025-04-07T13:34Z [---] followers, [---] engagements "#Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial $GMAB $ABBV #Genmab #AbbVie #Epkinly https://ashpublications.org/blood/article/doi/10.1182/blood.2024026830/535030/Epcoritamab-plus-GemOx-in-transplant-ineligible https://ashpublications.org/blood/article/doi/10.1182/blood.2024026830/535030/Epcoritamab-plus-GemOx-in-transplant-ineligible" [X Link](https://x.com/EgidiusLambrech/status/1910585164150808871) 2025-04-11T06:46Z [---] followers, [---] engagements "#Genmab $GMAB Rinatabart Sesutecan #GEN1184 📽 Tune into our video with Dr. Elizabeth K. Lee (@EKLee_MD) of @danafarber as she discusses treatment with with Rina-S; the agent showed antitumor activity in heavily pretreated patients with advanced #OvarianCancer. #MedEd 👉 Watch the video here: https://t.co/gNg68GwOV4 📽 Tune into our video with Dr. Elizabeth K. Lee (@EKLee_MD) of @danafarber as she discusses treatment with with Rina-S; the agent showed antitumor activity in heavily pretreated patients with advanced #OvarianCancer. #MedEd 👉 Watch the video here: https://t.co/gNg68GwOV4" [X Link](https://x.com/EgidiusLambrech/status/1912114575383633974) 2025-04-15T12:03Z [---] followers, [---] engagements "#Genmab $GMAB Rina-S #Rinatabart Sesutecan Elizabeth K. Lee MD of @DanaFarber discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer. @EKLee_MD Read the full article here: https://t.co/gHRh4xpMWa https://t.co/tGpSvxABpz Elizabeth K. Lee MD of @DanaFarber discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer. @EKLee_MD Read the full article here: https://t.co/gHRh4xpMWa https://t.co/tGpSvxABpz" [X Link](https://x.com/EgidiusLambrech/status/1916475212175999391) 2025-04-27T12:51Z [---] followers, [----] engagements "#Tepezza (teprotumumab) received a positive opinion from the CHMP for the treatment of adults with moderate to severe Thyroid Eye Disease (TED) also known as Graves Eye Diseas $AMGN $GMAB #Amgen #Genmab #Royalties #EMA https://www.ema.europa.eu/en/medicines/human/EPAR/tepezza https://www.ema.europa.eu/en/medicines/human/EPAR/tepezza" [X Link](https://x.com/EgidiusLambrech/status/1916733550449004763) 2025-04-28T05:57Z [---] followers, [---] engagements "Tepezza $AMGN $GMAB #Amgen #Genmab" [X Link](https://x.com/EgidiusLambrech/status/1917179509893112225) 2025-04-29T11:29Z [---] followers, [--] engagements "#Amgens #TEPEZZA (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom $AMGN $GMAB #Genmab https://www.businesswire.com/news/home/20250507246547/en/Amgens-TEPEZZA-teprotumumab-Granted-Marketing-Authorisation-as-the-First-Targeted-Treatment-Specifically-for-Adults-With-Moderate-to-severe-Thyroid-Eye-Disease-TED-in-the-United-Kingdomutm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork" [X Link](https://x.com/EgidiusLambrech/status/1920180903419994278) 2025-05-07T18:16Z [---] followers, [---] engagements "@BertrandBio it is exactly one of the points Genmab's Jan van de Winkel made when promoting Hexabody-CD38 in one of his conference calls; wouldn't it be fun if JNJ were to reconsider their decision to opt-out of Hexa-CD38 😂" [X Link](https://x.com/EgidiusLambrech/status/1922701797832937685) 2025-05-14T17:13Z [---] followers, [---] engagements "VIDEO: Response seen with Rina-S in ovarian cancer despite FR-alpha expression levels $GMAB #Genmab #Rinatabart Sesutecan https://www.healio.com/news/hematology-oncology/20250514/video-response-seen-with-rina-s-in-ovarian-cancer-despite-fr-alpha-expression-levelsutm_medium=social&utm_source=twitter&utm_campaign=sociallinks https://www.healio.com/news/hematology-oncology/20250514/video-response-seen-with-rina-s-in-ovarian-cancer-despite-fr-alpha-expression-levelsutm_medium=social&utm_source=twitter&utm_campaign=sociallinks" [X Link](https://x.com/EgidiusLambrech/status/1922924747676926445) 2025-05-15T07:59Z [---] followers, [---] engagements "#Rinatabart sesutecan (Rina-S) for patients with advanced #endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study. @Genmab $GMAB #ASCO25 https://meetings.asco.org/abstracts-presentations/246292 https://meetings.asco.org/abstracts-presentations/246292" [X Link](https://x.com/EgidiusLambrech/status/1925850614052892810) 2025-05-23T09:45Z [---] followers, [---] engagements "#Rinatabart sesutecan (Rina-S) #endometrial cancer @Genmab $GMAB #ASCO25 $GMAB - Endometrial cancer data on Genmabs Elahere rival beat forecast fuelling push into phase [--] - https://t.co/V2dQZxjW9m $GMAB - Endometrial cancer data on Genmabs Elahere rival beat forecast fuelling push into phase [--] - https://t.co/V2dQZxjW9m" [X Link](https://x.com/EgidiusLambrech/status/1925910680323936291) 2025-05-23T13:44Z [---] followers, [----] engagements "@Genmab $GMAB #AbbVie $ABBV #Epkinly #epcoritamab #ASCO25 CONGRESS #ASCO25 PRESENTATION @DrJulieVose @unmc @NebraskaMed shares insights on incorporating epcoritamab into clinical practice for the treatment of patients with R/R FL. They highlight results from the pivotal FL cohort of the EPCORE NHL-1 trial (N = 128) and discuss key https://t.co/kKgeGYjdzB CONGRESS #ASCO25 PRESENTATION @DrJulieVose @unmc @NebraskaMed shares insights on incorporating epcoritamab into clinical practice for the treatment of patients with R/R FL. They highlight results from the pivotal FL cohort of the EPCORE NHL-1" [X Link](https://x.com/EgidiusLambrech/status/1928717789826580542) 2025-05-31T07:38Z [---] followers, [---] engagements "@Genmab $GMAB #AbbVie $ABBV #Epkinly #epcoritamab #ASCO25 CONGRESS #ASCO25 POSTER Yasmin Karimi @Yhkarimi @UMich shares 3-year data from the pivotal EPCORE NHL-1 study of a subgroup of pts with R/R LBCL and CR at [--] years with epcoritamab monotherapy. About 96% of patients were still at CR at [--] years. Median DoCR PFS and OS not https://t.co/im8mxB0a9N CONGRESS #ASCO25 POSTER Yasmin Karimi @Yhkarimi @UMich shares 3-year data from the pivotal EPCORE NHL-1 study of a subgroup of pts with R/R LBCL and CR at [--] years with epcoritamab monotherapy. About 96% of patients were still at CR at [--] years." [X Link](https://x.com/EgidiusLambrech/status/1929237324878999858) 2025-06-01T18:03Z [---] followers, [---] engagements "#Genmab $GMAB #AbbVie $ABBV #Epkinly #epcoritamab #ASCO25 Two years after starting treatment with epcoritamab a subgroup of patients with relapsed or refractory #LBCL are showing long-term disease remission and overall survival according to post-hoc analysis data from EPCORE-NHL-1 presented at #ASCO25. 📰 https://t.co/TWvEirsH4w https://t.co/PgsxLyO8db Two years after starting treatment with epcoritamab a subgroup of patients with relapsed or refractory #LBCL are showing long-term disease remission and overall survival according to post-hoc analysis data from EPCORE-NHL-1 presented at" [X Link](https://x.com/EgidiusLambrech/status/1929808102989107488) 2025-06-03T07:51Z [---] followers, [---] engagements "#ASCO25: #Genmabs #Rina-S en route to blockbuster potential amid further positive data $GMAB #rinatabart sesutecan via @TrialsArena https://www.clinicaltrialsarena.com/news/asco25-genmabs-rina-s-en-route-to-blockbuster-potential-amid-further-positive-data/ https://www.clinicaltrialsarena.com/news/asco25-genmabs-rina-s-en-route-to-blockbuster-potential-amid-further-positive-data/" [X Link](https://x.com/EgidiusLambrech/status/1929876031722189087) 2025-06-03T12:21Z [---] followers, [---] engagements "#Genmab $GMAB #Epkinly" [X Link](https://x.com/EgidiusLambrech/status/1935039168532603275) 2025-06-17T18:17Z [---] followers, [--] engagements "EHA [----] J&J claims an extramedullary edge $JNJ $GMAB #Genmab #Talvey #Tecvayli https://www.oncologypipeline.com/apexonco/eha-2025-jj-claims-extramedullary-edge https://www.oncologypipeline.com/apexonco/eha-2025-jj-claims-extramedullary-edge" [X Link](https://x.com/EgidiusLambrech/status/1935208665423954139) 2025-06-18T05:31Z [---] followers, [---] engagements "#Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant #Genmab $GMAB #AbbVie $ABBV #Epkinly #EHA2025 via @AJMC https://www.ajmc.com/view/epcoritamab-plus-chemoimmunotherapy-yields-87-response-rate-in-r-r-dlbcl-65-proceed-to-transplant https://www.ajmc.com/view/epcoritamab-plus-chemoimmunotherapy-yields-87-response-rate-in-r-r-dlbcl-65-proceed-to-transplant" [X Link](https://x.com/EgidiusLambrech/status/1935209927053611361) 2025-06-18T05:36Z [---] followers, [---] engagements "RITUXIMAB AND #EPCORITAMAB AS #FIRST-LINE THERAPY FOR PATIENTS WITH HIGH-TUMOR BURDEN #FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIAL #Genmab $GMAB #AbbVie $ABBV #Epkinly #icml2025 https://onlinelibrary.wiley.com/doi/10.1002/hon.70094_227 https://onlinelibrary.wiley.com/doi/10.1002/hon.70094_227" [X Link](https://x.com/EgidiusLambrech/status/1935316655611199815) 2025-06-18T12:40Z [---] followers, [---] engagements "Results from EPCORE NHL-2 trial of #epcoritamab + R-CHOP for previously untreated DLBCL #Genmab $GMAB #AbbVie $ABBV #Epkinly #ICML2025 https://youtu.be/9sco80a47i4feature=shared https://youtu.be/9sco80a47i4feature=shared" [X Link](https://x.com/EgidiusLambrech/status/1935625131826745706) 2025-06-19T09:06Z [---] followers, [----] engagements "#Genmab $GMAB #AbbVie $ABBV #Epcoritamab #Epkinly #ICML2025 Bispecifics in the frontline In EPCORE NHL-5 Epcoritamab + pola-R-CHP in 1L DLBCL: ORR 100% CRR 97% 81% MRD by C3D1 (ctDNA) Durable deep responses. No ICANS. All CRS low grade. #ICML2025 #18ICML #lymsm https://t.co/tXXGx3AnwJ Bispecifics in the frontline In EPCORE NHL-5 Epcoritamab + pola-R-CHP in 1L DLBCL: ORR 100% CRR 97% 81% MRD by C3D1 (ctDNA) Durable deep responses. No ICANS. All CRS low grade. #ICML2025 #18ICML #lymsm https://t.co/tXXGx3AnwJ" [X Link](https://x.com/EgidiusLambrech/status/1935633294336594402) 2025-06-19T09:38Z [---] followers, [----] engagements "#Genmab $GMAB #AbbVie $ABBV #Epcoritamab #Epkinly #ICML2025 Also: matched analysis of epco-R-miniCHOP vs R-miniCHOP shows 64% risk of progression and 80% risk of death. CR rate: 92.8% vs 67.1%. Small N but a strong signal. #18ICML #lymsm https://t.co/g4APilDqQB Also: matched analysis of epco-R-miniCHOP vs R-miniCHOP shows 64% risk of progression and 80% risk of death. CR rate: 92.8% vs 67.1%. Small N but a strong signal. #18ICML #lymsm https://t.co/g4APilDqQB" [X Link](https://x.com/EgidiusLambrech/status/1935633437366645173) 2025-06-19T09:39Z [---] followers, [----] engagements "#DARZALEX (daratumumab) receives the first positive #CHMP opinion for patients with high-risk #smouldering multiple myeloma $JNJ $GMAB #Genmab $HALO #EMA https://www.globenewswire.com/news-release/2025/06/20/3102621/0/en/DARZALEX-daratumumab-receives-the-first-positive-CHMP-opinion-for-patients-with-high-risk-smouldering-multiple-myeloma.html https://www.globenewswire.com/news-release/2025/06/20/3102621/0/en/DARZALEX-daratumumab-receives-the-first-positive-CHMP-opinion-for-patients-with-high-risk-smouldering-multiple-myeloma.html" [X Link](https://x.com/EgidiusLambrech/status/1936011823196553444) 2025-06-20T10:42Z [---] followers, [---] engagements "Phase III trial of #rinatabart sesutecan in platinum-resistant ovarian cancer #Genmab $GMAB Rina-S @AngelesSecord https://www.youtube.com/watchv=JSXmQpDA71M https://www.youtube.com/watchv=JSXmQpDA71M" [X Link](https://x.com/EgidiusLambrech/status/1942501543065878884) 2025-07-08T08:30Z [---] followers, [---] engagements "FDA rejects new indication for Columvi Roche Genentech $ABBV $GMAB AbbVie Genmab #Epkinly #Epcoritamab via @onclive https://www.onclive.com/view/fda-issues-crl-for-glofitamab-plus-chemo-in-r-r-dlbcl https://www.onclive.com/view/fda-issues-crl-for-glofitamab-plus-chemo-in-r-r-dlbcl" [X Link](https://x.com/EgidiusLambrech/status/1947207891301073191) 2025-07-21T08:11Z [---] followers, [---] engagements "Trial results set up AbbVie Genmab's Epkinly for key expansion in follicular lymphoma https://www.fiercehealthcare.com/pharma/new-results-set-abbvie-genmabs-epkinly-key-expansion-follicular-lymphoma https://www.fiercehealthcare.com/pharma/new-results-set-abbvie-genmabs-epkinly-key-expansion-follicular-lymphoma" [X Link](https://x.com/EgidiusLambrech/status/1954976395072884798) 2025-08-11T18:41Z [---] followers, [---] engagements "#Epkinly bucks the delay trend #Genmab #AbbVie $GMAB $ABBV https://www.oncologypipeline.com/apexonco/epkinly-bucks-delay-trend https://www.oncologypipeline.com/apexonco/epkinly-bucks-delay-trend" [X Link](https://x.com/EgidiusLambrech/status/1954994797103784410) 2025-08-11T19:54Z [---] followers, [---] engagements "#GENMAB : target price raised by UBS UBS confirms its "buy" recommendation on Genmab shares with a target price raised from [----] to [----] Danish kronor $GMAB #MarketScreener https://www.marketscreener.com/news/genmab-target-price-raised-by-ubs-ce7c51dbda8bf62dutm_source=twitter&utm_medium=social&utm_campaign=share https://www.marketscreener.com/news/genmab-target-price-raised-by-ubs-ce7c51dbda8bf62dutm_source=twitter&utm_medium=social&utm_campaign=share" [X Link](https://x.com/EgidiusLambrech/status/1955560914440130844) 2025-08-13T09:23Z [---] followers, [----] engagements "Outpatient #Epcoritamab Demonstrates Efficacy and Safety in R/R DLBCL $GMAB #Genmab via @targetedonc https://www.targetedonc.com/view/outpatient-epcoritamab-demonstrates-efficacy-and-safety-in-r-r-dlbcl https://www.targetedonc.com/view/outpatient-epcoritamab-demonstrates-efficacy-and-safety-in-r-r-dlbcl" [X Link](https://x.com/EgidiusLambrech/status/1963614043786076433) 2025-09-04T14:44Z [---] followers, [---] engagements "New Phase [--] trial: Study to Assess the Efficacy and Safety of #Rina-S Compared to Treatment of Investigator's Choice in Participants With #Endometrial Cancer (RAINFOL-03) @Genmab $GMAB #Rinatabart Sesutecan https://clinicaltrials.gov/study/NCT07166094 https://clinicaltrials.gov/study/NCT07166094" [X Link](https://x.com/EgidiusLambrech/status/1965770207135506767) 2025-09-10T13:31Z [---] followers, [---] engagements "Fixed-Duration #Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory #Follicular Lymphoma ORR and complete response (CR) rate were 96% and 88% #Genmab #AbbVie $GMAB $ABBV #Epkinly https://ashpublications.org/blood/article/doi/10.1182/blood.2025029909/547148/Fixed-Duration-Epcoritamab-Plus-R2-Drives https://ashpublications.org/blood/article/doi/10.1182/blood.2025029909/547148/Fixed-Duration-Epcoritamab-Plus-R2-Drives" [X Link](https://x.com/EgidiusLambrech/status/1966047006566273408) 2025-09-11T07:51Z [---] followers, [---] engagements "$GMAB - Genmab: A Matter Of Time https://seekingalpha.com/article/4822275-genmab-a-matter-of-timesource=tweet https://seekingalpha.com/article/4822275-genmab-a-matter-of-timesource=tweet" [X Link](https://x.com/EgidiusLambrech/status/1966742885904126437) 2025-09-13T05:56Z [---] followers, [---] engagements "@PersimmonTI could Genmab be a fit" [X Link](https://x.com/EgidiusLambrech/status/1967247589323202721) 2025-09-14T15:22Z [---] followers, [---] engagements "@AaronRosenblum5 @cIubsandwich070 "Upon strategic evaluation we have decided to discontinue preparation for a Phase [--] study in second / third line squamous cell carcinoma of the head and neck" https://ir.genmab.com/static-files/9babf34b-bff3-40c7-a14c-29214f4f393a https://ir.genmab.com/static-files/9babf34b-bff3-40c7-a14c-29214f4f393a" [X Link](https://x.com/EgidiusLambrech/status/1969005805245480999) 2025-09-19T11:49Z [---] followers, [---] engagements "@AaronRosenblum5 @cIubsandwich070 no i haven't seen more. It could also be that Pfizer is less interested as they agreed to change the License agreement to transfer some of the Tisotumab responsibilities to Genmab" [X Link](https://x.com/EgidiusLambrech/status/1969027943906046251) 2025-09-19T13:16Z [---] followers, [--] engagements "New Novartis data further support benefits of #Kesimpta in relapsing MS following switch from oral disease modifying therapies $NVS $GMAB #Genmab https://www.novartis.com/news/media-releases/new-novartis-data-further-support-benefits-kesimpta-relapsing-ms-following-switch-from-oral-disease-modifying-therapiesutm_source=twitter&utm_medium=social&utm_campaign=2025-RMS-Data-ECTRIMS&utm_content=static-image-global" [X Link](https://x.com/EgidiusLambrech/status/1970779773329977579) 2025-09-24T09:18Z [---] followers, [---] engagements "Dr. Brian Durie provides details of the CASSIOPEIA trial mulitple #myeloma #Daratumumab #Genmab $GMXAY $JNJ key abstracts presented at #ASCO19 and #EHA2019 via @YouTube @IMFmyeloma https://youtu.be/NhuAkDVRAM4 https://youtu.be/NhuAkDVRAM4" [X Link](https://x.com/EgidiusLambrech/status/1139163263378345984) 2019-06-13T13:31Z [---] followers, [--] engagements "@Slambucket @_Rasga_ @VincentRK @NorthTxMSG @JackMAiello @MyelomaTeacher @mtmdphd @IMFmyeloma @MayoMyeloma Philippe Moreau: "I think that when we are going to use quadruplet combination including CD38 antibodies plus SCT we are going to #cure some young patients" in this interview on #daratumumab + VTd #EHA24 #Genmab #Myeloma https://www.targetedonc.com/news/daratumumab-improves-responses-pfs-in-newly-diagnosed-transplanteligible-myeloma https://www.targetedonc.com/news/daratumumab-improves-responses-pfs-in-newly-diagnosed-transplanteligible-myeloma" [X Link](https://x.com/EgidiusLambrech/status/1139819595089567744) 2019-06-15T08:59Z [---] followers, [--] engagements "@Orla_McCourt @MichaelodwyerMD @IrishTimes amazing isn't it how can they leave that out 😂 thanks for the link @MichaelodwyerMD #daratumumab seems 'to make every combination better' very interesting to see what the macrophage activation will add #EHA24 #Genmab #JNJ https://www.youtube.com/watchv=yK8YSahrd0w https://www.youtube.com/watchv=yK8YSahrd0w" [X Link](https://x.com/EgidiusLambrech/status/1139830524917293056) 2019-06-15T09:42Z [---] followers, [--] engagements "@BertrandBio they were disclosed a while ago SITC2018 had abstracts (you can search duobody) Genmab's IR recently said that the reason for PD-L1x4-1BB being slightly further progressed (as the CD40x4-1BB) has to do with prioritization and resource allocation. https://higherlogicdownload.s3.amazonaws.com/SITCANCER/7aaf41a8-2b65-4783-b86e-d48d26ce14f8/UploadedImages/Annual_Meeting_2018/Annual_Meeting/SITC_2018_Abstract_Book.pdf https://higherlogicdownload.s3.amazonaws.com/SITCANCER/7aaf41a8-2b65-4783-b86e-d48d26ce14f8/UploadedImages/Annual_Meeting_2018/Annual_Meeting/SITC_2018_Abstract_Book.pdf" [X Link](https://x.com/EgidiusLambrech/status/1140590597113356288) 2019-06-17T12:02Z [---] followers, [--] engagements "clinical determinants driving safety and efficacy of #Camidanlumab Tesirine (ADCT301) in relapsed/refractory Classical #Hodgkin #Lymphoma (CHL) ADCT-301 combines #Genmabs HuMax-TAC antibody and ADC Therapeutics PBD-based warhead and linker technology https://onlinelibrary.wiley.com/doi/10.1002/hon.61_2629 https://onlinelibrary.wiley.com/doi/10.1002/hon.61_2629" [X Link](https://x.com/EgidiusLambrech/status/1140609402472452096) 2019-06-17T13:17Z [---] followers, [--] engagements "In this five-part series that focuses on making sense of multiple #myeloma treatment Dr Brian Durie discussing Frontline Therapy with Dr. Joseph Mikhael and Dr. Philippe Moreau #Genmab $GMXAY $JNJ #Daratumumab #CASSIOPEIA #MAIA via @IMFmyeloma http://www.myeloma.org/node/2310 http://www.myeloma.org/node/2310" [X Link](https://x.com/EgidiusLambrech/status/1140950329539923969) 2019-06-18T11:52Z [---] followers, [--] engagements "#SITC2020: #GEN1046 or #DuoBody-PD-L1x4-1BB is jointly developed by #Genmab and #BioNTech using Genmabs DuoBody technology. It is designed to simultaneously block the PD-L1 axis and activate T-cells through conditional 4-1BB co-stimulation $GMAB $BNTX https://www.youtube.com/watchv=QmnXu-ZcoHM https://www.youtube.com/watchv=QmnXu-ZcoHM" [X Link](https://x.com/EgidiusLambrech/status/1325803832941613056) 2020-11-09T14:14Z [---] followers, [--] engagements "#Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death #Seagen CMO: "Our vedotin-based ADC research at #SITC2020 illustrates the impact of immunogenic cell death on the tumor microenvironment" $GMAB #Genmab $SGEN https://jitc.bmj.com/content/8/Suppl_3/A653 https://jitc.bmj.com/content/8/Suppl_3/A653" [X Link](https://x.com/EgidiusLambrech/status/1325812813017837573) 2020-11-09T14:49Z [---] followers, [--] engagements "#SITC2020 [---] Preclinical mechanism of action and pharmacodynamic biomarker studies of #DuoBody-CD3x5T4 in vitro and in vivo in solid cancer models $GMAB #Genmab $ABBV https://jitc.bmj.com/content/8/Suppl_3/A746 https://jitc.bmj.com/content/8/Suppl_3/A746" [X Link](https://x.com/EgidiusLambrech/status/1325815703337897984) 2020-11-09T15:01Z [---] followers, [--] engagements "@Genmab @biontech @Genmab please note that BioNTech already disclosed the updated data via their SEC filings https://investors.biontech.de/sec-filings/sec-filing/6-k/0001564590-20-052594 https://investors.biontech.de/sec-filings/sec-filing/6-k/0001564590-20-052594" [X Link](https://x.com/EgidiusLambrech/status/1326074735755730944) 2020-11-10T08:10Z [---] followers, [--] engagements "New #Epcoritamab trial by #Genmab & #AbbVie: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic #Leukemia $GMAB $ABBV #DuoBody-CD3xCD20 #GEN3013 #CLL https://www.clinicaltrials.gov/ct2/show/NCT04623541term=NCT04623541&draw=2&rank=1 https://www.clinicaltrials.gov/ct2/show/NCT04623541term=NCT04623541&draw=2&rank=1" [X Link](https://x.com/EgidiusLambrech/status/1326147051994951683) 2020-11-10T12:57Z [---] followers, [--] engagements "#Genmab and #BioNTech started the dose expansion for #GEN1046 (#DuoBody-PD-L14-1BB) in NSCLC It looks like [--] cohorts are planned 2x NSCLC Urothelial Endometrial Triple-negative breast cancer Squamous Cell Carcinoma of the Head and Neck and Cervical $GMAB $BNTX #BNT311" [X Link](https://x.com/EgidiusLambrech/status/1326181492129722374) 2020-11-10T15:14Z [---] followers, [--] engagements "Next-Generation Bispecific Antibody Shows Early Clinical Activity in Advanced Solid Tumors #Genmab and #BioNTech show early data on #GEN1046 (#DuoBody-PD-L14-1BB) at #SITC2020 $GMAB $BNTX #BNT311 via @onclive https://www.onclive.com/view/next-generation-bispecific-antibody-shows-early-clinical-activity-in-advanced-solid-tumors https://www.onclive.com/view/next-generation-bispecific-antibody-shows-early-clinical-activity-in-advanced-solid-tumors" [X Link](https://x.com/EgidiusLambrech/status/1327159747594899456) 2020-11-13T08:01Z [---] followers, [--] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@EgidiusLambrech E Lambrechts
E Lambrechts posts on X about $gmab, $jnj, $abbv, $pfe the most. They currently have [------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [---] +20%
- [--] Month [------] +623%
- [--] Months [------] +25%
- [--] Year [------] -8.20%
Mentions: [--] #
- [--] Month [--] +69%
- [--] Months [---] +120%
- [--] Year [---] +75%
Followers: [------] #
- [--] Week [---] -0.29%
- [--] Month [---] no change
- [--] Months [---] no change
- [--] Year [---] +2.10%
CreatorRank: [---------] #
Social Influence
Social category influence stocks countries finance currencies technology brands social networks us election cryptocurrencies travel destinations exchanges
Social topic influence $gmab #2, $jnj, $abbv #48, $pfe, $gmxay, target, $sgen, $nvs, acasunlimab, $nvo
Top assets mentioned Johnson & Johnson (JNJ) AbbVie Inc (ABBV) Pfizer, Inc. (PFE) Seagen Inc (SGEN) Novartis AG (NVS) Novo-Nordisk (NVO) Merus N.V. Common Shares (MRUS) Amgen, Inc. (AMGN) Frontline Ltd. (FRO) Halozyme Therapeutics, Inc. (HALO) Morgan Stanley (MS) Bank of America (BAC) Sanofi (SNY) AstraZeneca PLC (AZN) ROGin AI (ROG) Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP)
Top Social Posts
Top posts by engagements in the last [--] hours
"Teprotumumab is a fully human antibody developed by/with #Genmab $GMXAY Horizon Pharma Announces Phase [--] Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease (TED) Met Primary and All Secondary Endpoints https://www.businesswire.com/news/home/20190228005255/en/Horizon-Pharma-plc-Announces-Phase-3-Confirmatory#.XHftc6htgA8.twitter https://www.businesswire.com/news/home/20190228005255/en/Horizon-Pharma-plc-Announces-Phase-3-Confirmatory#.XHftc6htgA8.twitter"
X Link 2019-02-28T14:23Z [---] followers, [--] engagements
"Nice interview with the charismatic #Genmab CEO Jan van de Winkel (in english) $GMXAY #daratumumab https://play.borsen.dk/klip/5c72d71a595ab4f00a32f5b8 https://play.borsen.dk/klip/5c72d71a595ab4f00a32f5b8"
X Link 2019-03-01T14:39Z [---] followers, [--] engagements
"#Tisotumab vedotin is being developed in collaboration with @Genmab #pipeline #Cervical Cancer $GMXAY"
X Link 2019-03-29T13:25Z [---] followers, [--] engagements
"New @Genmab #Duobody trial : GEN1046 Safety Trial in Patients With Malignant Solid Tumors GEN1046 = DuoBody PD-L1x4-1BB in collaboration with BioNTech $GMXAY https://clinicaltrials.gov/ct2/show/NCT03917381term=NCT03917381&rank=1 https://clinicaltrials.gov/ct2/show/NCT03917381term=NCT03917381&rank=1"
X Link 2019-04-17T14:08Z [---] followers, [--] engagements
"Novel Agent Reduces Bulging Eyes in Thyroid Eye Disease / Graves' orbitopathy #Teprotumumab is a fully human antibody developed by #Genmab. Clinical development now conducted by #Horizon Pharma. $GMXAY #Royalties https://www.medpagetoday.com/meetingcoverage/aace/79493 https://www.medpagetoday.com/meetingcoverage/aace/79493"
X Link 2019-04-29T12:44Z [---] followers, [--] engagements
"#Daratumumab as Frontline Treatment for Multiple #Myeloma - by Dr. @szusmani #Genmab $GMXAY $JNJ via @YouTube @TargetedOnc https://youtu.be/le6XDnI0wAE https://youtu.be/le6XDnI0wAE"
X Link 2019-05-02T13:33Z [---] followers, [--] engagements
"good news for #Genmab as [--] of these potential blockbusters use Genmab's DuoBody technology the BCMA/CD3 (JNJ-7957) and the EGFR + cMet (JNJ-6372). I think on the second Genmab may even get double #royalties as I think they made both arms $JNJ $GMXAY J&J polishes up its new list of late-stage blockbuster candidates and cancer remains big $JNJ https://t.co/aipHhfCmSj J&J polishes up its new list of late-stage blockbuster candidates and cancer remains big $JNJ https://t.co/aipHhfCmSj"
X Link 2019-05-15T15:23Z [---] followers, [--] engagements
"#Genmab products featured in the Johnson & Johnson [----] Pharmaceutical Business Review. Offcourse Darzalex and [--] #DuoBody antibodies [--] of which are mentioned as $ [--] billion potential #royalties $GMXAY $JNJ #Daratumumab"
X Link 2019-05-16T13:05Z [---] followers, [--] engagements
"#Genmab #Daratumumab $GMXAY $JNJ #Darzalex #Myeloma"
X Link 2019-05-16T13:09Z [---] followers, [--] engagements
"#Genmab #DuoBody platform being used by Johnson & Johnson $GMXAY $JNJ #Daratumumab #Myeloma #royalties"
X Link 2019-05-16T13:12Z [---] followers, [--] engagements
"Apparantly the CD33xCD3 is also a #Genmab #DuoBody it was just updated on the Genmab website It also shows another one JNJ-63898081 for #Prostate Cancer #Solid tumors So now [--] Genmab duobodies in development by Johnson & Johnson $JNJ $GMXAY #ASCO19 http://www.genmab.com/product-pipeline/products-in-development #Genmab products featured in the Johnson & Johnson [----] Pharmaceutical Business Review. Offcourse Darzalex and [--] #DuoBody antibodies [--] of which are mentioned as $ [--] billion potential #royalties $GMXAY $JNJ #Daratumumab https://t.co/wrbV1V5Uey"
X Link 2019-05-17T07:33Z [---] followers, [--] engagements
"Another new $JNJ trial using #Genmab #DuoBody technology this time in #Solid tumors #prostate cancer. A Study of JNJ-63898081 in Participants With Advanced Stage #Solid Tumors $GMXAY https://clinicaltrials.gov/ct2/show/NCT03926013 http://GEN.CO https://clinicaltrials.gov/ct2/show/NCT03926013 http://GEN.CO"
X Link 2019-05-23T14:10Z [---] followers, [--] engagements
"Phase [--] #COLUMBA Study Investigating a #Subcutaneous Formulation of DARZALEX (#daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple #Myeloma #Genmab #asco19 $JNJ $GMXAY https://www.janssen.com/phase-3-columba-study-investigating-subcutaneous-formulation-darzalex-daratumumab-showed-non https://www.janssen.com/phase-3-columba-study-investigating-subcutaneous-formulation-darzalex-daratumumab-showed-non"
X Link 2019-06-03T07:18Z [---] followers, [--] engagements
"#Daratumumab approval in China @Genmab $GMXAY $GMAB $JNJ http://www.nmpa.gov.cn/WS04/CL2056/338825.html Darzalex(Daratumumab) a CD38-directed cytolytic antibody was approved by NMPA as monotherapy for the treatment of relapsed or refractory multiple myeloma patients who have received prior therapies including a proteasome inhibitor and an immunomodulatory agent. https://t.co/qaTdiCZ4hD http://www.nmpa.gov.cn/WS04/CL2056/338825.html Darzalex(Daratumumab) a CD38-directed cytolytic antibody was approved by NMPA as monotherapy for the treatment of relapsed or refractory multiple myeloma patients"
X Link 2019-07-05T08:41Z [---] followers, [--] engagements
"SMC recommends #Darzalex as second-line treatment for multiple #myeloma (The Scottish Medicines Consortium) #daratumumab #Genmab $GMXAY $GMAB $JNJ via @Pharmafield https://pharmafield.co.uk/pharma_news/smc-recommends-darzalex-as-second-line-treatment-for-multiple-myeloma/ https://pharmafield.co.uk/pharma_news/smc-recommends-darzalex-as-second-line-treatment-for-multiple-myeloma/"
X Link 2019-07-08T14:10Z [---] followers, [--] engagements
"#Teprotumumab is a fully human antibody developed by #Genmab. Clinical development now conducted by #Horizon Pharma. #Graves' orbitopathy #ThyroidEyeDisease $GMXAY $GMAB #Royalties NEWS: Today we announced that weve submitted a Biologics License Application (BLA) to the FDA for our investigational medicine for the treatment of active #ThyroidEyeDisease (TED). Read the full press release here: https://t.co/xUBjbpGR25. https://t.co/UCcczaL0nA NEWS: Today we announced that weve submitted a Biologics License Application (BLA) to the FDA for our investigational medicine for the treatment of active"
X Link 2019-07-10T11:16Z [---] followers, [--] engagements
"Morgan Stanley raises EPS estimates for #Genmab Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and $31 price target on $GMAB and raised his EPS estimates for FY20 and FY21. https://thefly.com/landingPageNews.phpid=3048529 https://thefly.com/landingPageNews.phpid=3048529"
X Link 2020-03-11T13:34Z [---] followers, [--] engagements
"#Genmab investor presentation June [----] $GMAB $JNJ $ABV $BNTX $SGEN $NVS https://ir.genmab.com/static-files/411621e5-4366-4690-84b1-081308db8a83 https://ir.genmab.com/static-files/411621e5-4366-4690-84b1-081308db8a83"
X Link 2020-06-18T14:07Z [---] followers, [--] engagements
"@dlacalle_IA I think one would have to look at Total GDP to make that statement you are looking at growth numbers [----] GDP was 2.445bn ; H1 [--] is already at 1.619bn. Awfull number nonetheless. https://www.destatis.de/EN/Themes/Economy/National-Accounts-Domestic-Product/Tables/lrvgr02.html https://www.destatis.de/EN/Themes/Economy/National-Accounts-Domestic-Product/Tables/lrvgr02.html"
X Link 2020-07-30T12:58Z [---] followers, [--] engagements
"Novo Nordisk turns up the heat on inlicensed #Genmab drug with phase III preparations #MIM8 $NVO $NOVO $GMAB #Royalties https://medwatch.com/News/Pharma___Biotech/article13308259.ece https://medwatch.com/News/Pharma___Biotech/article13308259.ece"
X Link 2021-09-23T14:08Z [---] followers, [--] engagements
"#Kesimpta sales Q3 '21 $109mn (YTD $225mn) #Genmab is entitled to 10% royalties on net sales of Kesimpta $NVS $NOVN.SW $GMAB #Ofatumumab"
X Link 2021-10-26T06:47Z [---] followers, [--] engagements
"Genmab A/S (GEN:DC) $GMAB PT Raised to DKK3200 at Bernstein via @Street_Insider https://www.streetinsider.com/Analyst+Comments/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK3%2C200+at+Bernstein/19413231.html https://www.streetinsider.com/Analyst+Comments/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK3%2C200+at+Bernstein/19413231.html"
X Link 2022-01-05T15:15Z [---] followers, [--] engagements
"Novo Nordisk spies great #hemophilia opportunities with partner #Genmab Mim8 is a bispecific antibody created under a collaboration between $GMAB and $NVO using Genmabs DuoBody technology and the first DuoBody candidate outside of oncology. https://medwatch.com/News/Pharma___Biotech/article13701763.ece https://medwatch.com/News/Pharma___Biotech/article13701763.ece"
X Link 2022-02-03T13:05Z [---] followers, [--] engagements
"$NVO $GMAB @Genmab #Mim8 Pratima Chowdary presented data on the FVIIIa mimetic Mim8 in the phase 1/2 FRONTIER-1 trial in healthy individuals and those with haemophilia A. 25% of AEs could be drug related higher dose cohorts had few bleeds. #ISTH2022 https://t.co/xjjT3KtIAJ Pratima Chowdary presented data on the FVIIIa mimetic Mim8 in the phase 1/2 FRONTIER-1 trial in healthy individuals and those with haemophilia A. 25% of AEs could be drug related higher dose cohorts had few bleeds. #ISTH2022 https://t.co/xjjT3KtIAJ"
X Link 2022-07-11T14:52Z [---] followers, [--] engagements
"#Epcoritamab $GMAB $ABBV #Genmab #AbbVie New clinical trial: A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma https://t.co/HtWwyP8kN4 #DLBCL #lymsm #hematology New clinical trial: A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma https://t.co/HtWwyP8kN4 #DLBCL #lymsm"
X Link 2022-07-12T10:46Z [---] followers, [--] engagements
"Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK2900 at Barclays via @Street_Insider https://www.streetinsider.com/Analyst+Comments/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C900+at+Barclays/20338159.html https://www.streetinsider.com/Analyst+Comments/Genmab+AS+%28GEN%3ADC%29+%28GMAB%29+PT+Raised+to+DKK2%2C900+at+Barclays/20338159.html"
X Link 2022-07-19T06:54Z [---] followers, [--] engagements
"@FiercePharma any idea what happened to the earlier deal with Halozyme Therapeutics with the same purpose (coincidentally exactly to the day 2yrs ago.indicating perhaps that contract had some 2yr clause) https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-and-halozyme-therapeutics-inc-enter https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-and-halozyme-therapeutics-inc-enter"
X Link 2022-11-28T18:34Z [---] followers, [--] engagements
"of interest to #Genmab as they share a 50:50 partnership on #Tivdak (Tisotumab Vedotin) $GMAB $SGEN"
X Link 2023-03-13T13:50Z [---] followers, [---] engagements
"of interest to #Genmab for Provention Bio asset PRV-015 for Celiac Disease (PRV-015 was initially developed by Genmab as HuMax-IL15) $GMAB"
X Link 2023-03-13T13:51Z [---] followers, [---] engagements
"Reid Merryman MD on High-Risk Follicular Lymphoma: New Data on #Epcoritamab Rituximab and Lenalidomide #Genmab #AbbVie $GMAB $ABBV"
X Link 2023-06-14T12:16Z [---] followers, [--] engagements
"Frontline Treatment With #Epcoritamab Plus R-CHOP for Patients With High-Risk DLBCL - Updated EPCORE NHL-2 Data #Genmab #AbbVie $GMAB $ABBV"
X Link 2023-06-20T09:05Z [---] followers, [---] engagements
"Preclinical anti-tumour activity of #HexaBody-CD38 anext-generation CD38 antibody with superior complement-dependent cytotoxic activity otherwise known as 'SuperDara' 😄 @Genmab $GMAB $JNJ #Darzalex #Daratumumab"
X Link 2023-06-29T12:01Z [--] followers, [---] engagements
"#Genmab Announces AbbVie Receives Positive #CHMP Opinion for #Epcoritamab (TEPKINLY) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) $GMAB $ABBV"
X Link 2023-07-21T08:42Z [---] followers, [--] engagements
"Janssen Receives Positive CHMP Opinions for Novel Bispecific Antibodies TALVEY(#talquetamab) and TECVAYLI(#teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma $JNJ $GMAB #Genmab #Royalties"
X Link 2023-07-21T14:22Z [---] followers, [--] engagements
"#Teclistamab #Tecvayli $GMAB #Genmab $JNJ 🚨 NEWS 🚨 @EMA_News CHMP recommends a new dosing schedule for teclistamab a BCMA/CD3-targeted bispecific antibody for the treatment of RRMM with [--] prior therapies including an IMiD PI and an anti-CD38 antibody with observed disease progression. https://t.co/mbKavMm5Nz 🚨 NEWS 🚨 @EMA_News CHMP recommends a new dosing schedule for teclistamab a BCMA/CD3-targeted bispecific antibody for the treatment of RRMM with [--] prior therapies including an IMiD PI and an anti-CD38 antibody with observed disease progression. https://t.co/mbKavMm5Nz"
X Link 2023-07-25T12:03Z [---] followers, [----] engagements
"U.S. #FDA Approves #TALVEY (#talquetamab-tgvs) a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple #Myeloma $JNJ $GMAB #Genmab #Royalties"
X Link 2023-08-10T10:59Z [---] followers, [---] engagements
"@Abdallah81MD @JanssenGlobal @sanofi @bmsnews @Amgen you might want to add @Genmab as [--] of those originated there with a possible 4th on the way with Hexabody-CD38 $GMAB"
X Link 2023-08-19T07:39Z [---] followers, [---] engagements
"European Commission Approves Reduced Dosing Frequency for Janssens Bispecific Antibody #TECVAYLI (#teclistamab) #Genmab $GMAB $JNJ"
X Link 2023-08-21T08:22Z [---] followers, [---] engagements
"$JNJ Submits Supplemental Biologics License Application to the U.S. FDA for #RYBREVANT combo (#amivantamab-vmjw) with #Chemo for #First-line Locally Advanced or Metastatic EGFR Exon [--] Insertion Mutation-Positive Non-Small Cell Lung Cancer #Genmab $GMAB"
X Link 2023-08-25T12:28Z [---] followers, [---] engagements
"Transcript: Johnson & Johnson at Morgan Stanley Global Healthcare Conference - Sep '23 $JNJ Also of interest for #Genmab as many products discussed are $GMAB originated; Darzalex Tecvayli Talvey and Rybrevant #Royalties https://johnsonandjohnson.gcs-web.com/static-files/0393dab9-a719-4b65-9aad-225403522a5f https://johnsonandjohnson.gcs-web.com/static-files/0393dab9-a719-4b65-9aad-225403522a5f"
X Link 2023-09-19T12:43Z [---] followers, [---] engagements
"Top [--] Best-Selling Drugs Of Q2 [----] - #Darzalex entered the list $JNJ $GMAB #Genmab #Royalties #Daratumumab"
X Link 2023-09-25T13:15Z [---] followers, [---] engagements
"#RYBREVANT and lazertinib compared to osimertinib First pivotal study to show a clinically meaningful benefit in a chemotherapy-free regimen versus osimertinib #amivantamab EGFR-Mutated Non-Small Cell Lung Cancer $JNJ $GMAB #Genmab #Royalties"
X Link 2023-09-28T11:56Z [---] followers, [---] engagements
"Expansion Trial of #Epcoritamab Shows Promising Antitumor Activity in Patients With High-Risk Relapsed/Refractory #CLL @Genmab $GMAB #AbbVie $ABBV via @targetedonc https://www.targetedonc.com/view/expansion-trial-of-epcoritamab-shows-promising-antitumor-activity-in-patients-with-high-risk-relapsed-refractory-cll https://www.targetedonc.com/view/expansion-trial-of-epcoritamab-shows-promising-antitumor-activity-in-patients-with-high-risk-relapsed-refractory-cll"
X Link 2023-10-09T15:29Z [---] followers, [----] engagements
"#AbbVie's #EPKINLY (#epcoritamab) receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to treat adult patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (#DLBCL) #Genmab $GMAB $ABBV"
X Link 2023-10-17T11:31Z [---] followers, [---] engagements
"@BertrandBio @Kevin_M_Biotech JNJ execs yesterday mentioned 'Our regimen is a chemo-free option for patients which we think is important' which i assume may be their selling point. Meanwhile $JNJ hardly moves and $AZN -3.3% pre-market. 🤔"
X Link 2023-10-18T12:37Z [---] followers, [---] engagements
"@BertrandBio @Kevin_M_Biotech yes i guess that may be the real question. curious for KOL comments over the weekend but maybe we need some extra months of data for a real answer"
X Link 2023-10-18T12:50Z [---] followers, [--] engagements
"UK approval for #Tepkinly (#epcoritamab) $GMAB $ABBV #Genmab #AbbVie"
X Link 2023-10-20T11:38Z [---] followers, [----] engagements
"Ph3 innovaTV [---] Trial Shows Potential of #Tisotumab Vedotin in #Cervical Cancer #Tivdak demonstrated a 30% reduction in the risk of death compared with investigators choice of chemotherapy $GMAB $SGEN $PFE #Genmab #Seagen #Pfizer via @targetedonc"
X Link 2023-10-23T08:01Z [---] followers, [---] engagements
"Professor Ignace Vergote reports on key results from ESMO Congress [----] on the innovaTV [---] trial -Recurrent or Metastatic #Cervical Cancer #Tisotumab Vedotin #Tivdak $GMAB $SGEN $PFE #Genmab #Seagen #Pfizer"
X Link 2023-10-23T14:53Z [---] followers, [---] engagements
"ESMO [----] Neues zu #Tisotumab Vedotin beim metastasierten Gebrmutterhalskrebs ab [--]. Linie. #Tivdak $GMAB $SGEN $PFE #Genmab #Seagen #Pfizer #ESMO23 via @YouTube"
X Link 2023-10-25T07:42Z [---] followers, [---] engagements
"#ESMO23 Expert video report on #amivantamab in combination therapy for 1L treatment in EGFRm advanced NSCLC #Rybrevant $JNJ $GMAB #Genmab #Royalties"
X Link 2023-10-30T11:35Z [---] followers, [---] engagements
"#Cervical cancer drug raises survival rate by 30% compared to chemotherapy: Game-changer #TIVDAK's bombshell results in phase [--] trial change the standard of care says lead researcher #Tisotumab $GMAB $SGEN $PFE Genmab Seagen Pfizer #ESMO23 #FoxNews https://www.foxnews.com/health/cervical-cancer-drug-increased-survival-rate-30-percent-chemotherapy-game-changer https://www.foxnews.com/health/cervical-cancer-drug-increased-survival-rate-30-percent-chemotherapy-game-changer"
X Link 2023-11-02T10:17Z [---] followers, [---] engagements
"#Tisotumab Vedotin for Metastatic #Cervical Cancer: Results From ESMO [----] With Brian Slomovitz MD #Tivdak $GMAB $SGEN $PFE Genmab Seagen Pfizer #ESMO23"
X Link 2023-11-02T11:08Z [---] followers, [---] engagements
"#Tisotumab Vedotin vs. Investigator's Choice in Cervical Cancer Dr. Slomovitz MD offers expert insights shedding light on this innovative therapy's significance in improving outcomes for patients #Tivdak $GMAB $SGEN $PFE Genmab Seagen Pfizer #ESMO23"
X Link 2023-11-03T12:00Z [---] followers, [---] engagements
"Subcutaneous #epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma - EPCORE NHL-3 #Epkinly $GMAB $ABBV #Genmab #AbbVie"
X Link 2023-11-04T08:20Z [---] followers, [---] engagements
"#Genmab's COO on launch of new cancer hope: It's gone better than expected Were seeing really strong uptake for #Epkinly says $GMAB s Chief Operating Officer Anthony Mancini. #Epcoritamab $ABBV"
X Link 2023-11-08T07:48Z [---] followers, [---] engagements
"$JNJ submits Supplemental Biologics License Application to U.S. FDA for Approval of #RYBREVANT (#amivantamab) + Chemotherapy for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Progressed on or after Osimertinib $GMAB #Genmab"
X Link 2023-11-20T15:49Z [---] followers, [----] engagements
"#Darzalex Late-Breaker @ #ASH23 #Daratumumab + Bortezomib Lenalidomide & Dexamethasone (VRd) Versus Vrd Alone in patients with newly diagnosed Multiple Myeloma (NDMM) who are eligible for ASCT: Primary Results of the Perseus Trial $GMAB #Genmab $JNJ"
X Link 2023-11-21T14:32Z [---] followers, [---] engagements
"Janssen submits Application to the #European Medicines Agency for #RYBREVANT (#amivantamab) + Chemotherapy for the Treatment of Adult Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer After Failure of Prior Therapy $GMAB #Genmab $JNJ #EMA"
X Link 2023-11-24T08:13Z [---] followers, [----] engagements
"* FDA grants Breakthrough Therapy Designation * European Medicines Agency (EMA) validates regulatory application for #epcoritamab for R/R Follicular Lymphoma (FL) after two or more lines of systemic therapy #Genmab #AbbVie $GMAB $ABBV EPKINLY/TEPKINLY"
X Link 2023-11-27T13:04Z [---] followers, [---] engagements
"#Amivantamab $JNJ $GMAB #Genmab The addition of amivantamab to chemotherapy in patients with advanced nonsmall-cell lung cancer with EGFR exon [--] insertions resulted in significantly longer progression-free survival. Full results of the PAPILLON trial: https://t.co/wEeOGpV5Wu #Oncology The addition of amivantamab to chemotherapy in patients with advanced nonsmall-cell lung cancer with EGFR exon [--] insertions resulted in significantly longer progression-free survival. Full results of the PAPILLON trial: https://t.co/wEeOGpV5Wu #Oncology"
X Link 2023-11-30T08:01Z [---] followers, [----] engagements
"#Tisotumab Vedotin Survival Data in #Cervical Cancer Are Game-Changing Treatment with #Tivdak may be a standard of care in second- or third-line recurrent or metastatic cervical cancer says Brian Slomovitz MD $GMAB $SGEN $PFE Genmab Seagen Pfizer https://www.cancernetwork.com/view/tisotumab-vedotin-survival-data-in-cervical-cancer-are-game-changing- https://www.cancernetwork.com/view/tisotumab-vedotin-survival-data-in-cervical-cancer-are-game-changing-"
X Link 2023-11-30T11:45Z [---] followers, [---] engagements
"#Genmab reports promising results for elusive lymphoma candidate #Epcoritamab $GMAB $ABBV #AbbVie #ASH23"
X Link 2023-12-11T07:57Z [---] followers, [---] engagements
"Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen #Tivdak #Tisotumab Vedotin $GMAB #Genmab $SGEN $PFE https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-all-required-regulatory-approvals-complete https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-all-required-regulatory-approvals-complete"
X Link 2023-12-12T12:44Z [---] followers, [---] engagements
"Behandeling multipel myeloom aangevuld met de antistof #daratumumab $JNJ $GMAB #Genmab #Darzalex"
X Link 2023-12-15T10:27Z [---] followers, [---] engagements
"First line #amivantamab submission filed: $JNJ submits sBLA and New Drug Application to U.S. FDA seeking Approval of #RYBREVANT Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) / MARIPOSA $GMAB #Genmab"
X Link 2023-12-21T15:38Z [---] followers, [---] engagements
"and the #amivantamab MARIPOSA EMA filing; impressive $JNJ $GMAB #Genmab"
X Link 2023-12-21T15:53Z [---] followers, [---] engagements
"New Ph3 trial 1st line Subcutaneous #Epcoritamab in combination with Intravenous Rituximab and Oral Lenalidomide (R2) -Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) #Genmab #AbbVie $GMAB $ABBV EPKINLY/TEPKINLY"
X Link 2024-01-05T14:39Z [---] followers, [---] engagements
"$JNJ $GMAB #Genmab "Duato noted that J&Js [----] sales projection for new multiple myeloma entrant #Tecvayli is 25% higher than Wall Streets estimate for the same year. For another bispecific #Talvey J&Js expected sales figure in [----] doubles analyst expectations" JPM24: Johnson & Johnson CEO says Tecvayli Talvey and several other meds are set to trounce analyst estimates https://t.co/A976oB1n4y JPM24: Johnson & Johnson CEO says Tecvayli Talvey and several other meds are set to trounce analyst estimates https://t.co/A976oB1n4y"
X Link 2024-01-09T09:06Z [---] followers, [----] engagements
"Interview with Tahi Ahmadi Chief Medical Officer at #Genmab and Jacqueline Nielsen Therapeutic Area Head for Hematology at #AbbVie on #epcoritamab for patients with relapsed/refractory Follicular Lymphoma $GMAB $ABBV #Epkinly #Tepkinly"
X Link 2024-01-17T13:55Z [---] followers, [---] engagements
"#Epkinly approved in brazil #Epcoritamab #Genmab #AbbVie $GMAB $ABBV ANVISA aprova EPKINLY (epcoritamabe) primeiro anticorpo biespecfico (DuoBody-CD3xCD20) para tratamento de linfoma difuso de grandes clulas B recidivo ou refratrio"
X Link 2024-01-30T10:16Z [---] followers, [---] engagements
"UK NICE #Epcoritamab #Tepkinly #Genmab #AbbVie $GMAB $ABBV NICE Recommends Subcutaneous Treatment Option Tepkinly (epcoritamab) for EligibleAdults with Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy https://t.co/s9AjFcflzo NICE Recommends Subcutaneous Treatment Option Tepkinly (epcoritamab) for EligibleAdults with Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy https://t.co/s9AjFcflzo"
X Link 2024-02-01T09:13Z [---] followers, [----] engagements
"$JNJ Submits Extension to the European Medicines Agency Seeking Approval of #RYBREVANT (amivantamab) in combination with Lazertinib for the #First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer #Genmab $GMAB #MARIPOSA #EMA"
X Link 2024-02-08T20:03Z [---] followers, [---] engagements
"#Tisotumab Vedotin (Tissue Factor ADC) Planned China submissions [----] - Zai Lab to submit an NDA to the NMPA in second-line+ cervical cancer. $GMAB $PFE #Genmab #Pfizer #Tivdak https://www.businesswire.com/news/home/20240227802106/en/Zai-Lab-Announces-Full-Year-2023-Financial-Results-and-Recent-Corporate-Updates https://www.businesswire.com/news/home/20240227802106/en/Zai-Lab-Announces-Full-Year-2023-Financial-Results-and-Recent-Corporate-Updates"
X Link 2024-02-28T15:20Z [---] followers, [---] engagements
"$GMAB $ABBV #Genmab #AbbVie #epcoritamab #Tepkinly NICE UK People with a type of lymphoma can be offered a new treatment option to fight a type of abnormal white blood cell that builds up in the lymph nodes or other organs. Epcoritamab is recommended for use in the NHS in England. Learn more: https://t.co/mskqyH4O6i #NICENews https://t.co/cRHw7hntMP People with a type of lymphoma can be offered a new treatment option to fight a type of abnormal white blood cell that builds up in the lymph nodes or other organs. Epcoritamab is recommended for use in the NHS in England. Learn more:"
X Link 2024-03-06T12:40Z [---] followers, [---] engagements
"Johnson & Johnson submits application to the European Medicines Agency for #DARZALEX (daratumumab)-based #quadruplet therapy for the treatment of patients with transplant-eligible #newly diagnosed multiple myeloma #PERSEUS #EMA $JNJ $GMAB #Genmab"
X Link 2024-03-06T14:02Z [---] followers, [---] engagements
"#Epcoritamab a Promising Therapy for #Richter Syndrome $GMAB $JNJ #Genmab #AbbVie #Tepkinly"
X Link 2024-03-07T11:20Z [---] followers, [---] engagements
"#Genmab said on March [--] that it has filed its bispecific antibody #Epkinly (#epcoritamab) being codeveloped with #AbbVie for an additional indication of relapsed or refractory follicular #lymphoma (Grade 1-3A) in #Japan. $GMAB $ABBV https://pj.jiho.jp/article/250573 https://pj.jiho.jp/article/250573"
X Link 2024-03-12T12:16Z [---] followers, [---] engagements
"Darzalex $JNJ $GMAB #Genmab UPDATE: US FDA Priority Review received for Phase [--] PERSEUS submission UPDATE: US FDA Priority Review received for Phase [--] PERSEUS submission"
X Link 2024-03-26T20:54Z [---] followers, [----] engagements
"@BertrandBio OTHER ONCOLOGY this quarter only Talvey and Rybrevant then I guess or can you think of anything else in there $178mn $JNJ $GMAB"
X Link 2024-04-16T12:45Z [---] followers, [---] engagements
"US FDA mandates label updates on CAR-T cancer therapies "participants receiving treatment with these products should be monitored life-long for secondary malignancies" $JNJ Carvykti $NVS Kymriah $GILD Yescarta $GMAB via @YahooFinance https://finance.yahoo.com/news/us-fda-mandates-label-updates-223309187.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr https://finance.yahoo.com/news/us-fda-mandates-label-updates-223309187.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr"
X Link 2024-04-19T11:59Z [---] followers, [---] engagements
"#Rybrevant - positive opinion on variation to marketing authorisation European Medicines Agency PAPILLON- with carboplatin and pemetrexed for the firstline treatment of advanced NSCLC with activating EGFR Exon20 $JNJ $GMAB #Genmab #Amivantamab #EMA https://www.ema.europa.eu/en/medicines/human/variation/rybrevant https://www.ema.europa.eu/en/medicines/human/variation/rybrevant"
X Link 2024-04-26T12:40Z [---] followers, [---] engagements
"AMGEN TO SUBMIT #TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY #EMA $AMGN $GMAB #Genmab #Tepezza https://prn.to/3w6VCZh https://prn.to/3w6VCZh"
X Link 2024-04-26T13:39Z [---] followers, [---] engagements
"#NovoNordisk: Mim8 demonstrates superior reduction of treated bleeding episodes -haemophilia A $NVO #Mim8 is a bispecific antibody created under a collaboration between #Genmab and Novo Nordisk using $GMAB s DuoBody technology. #Royalties #Milestones https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.htmlid=168515 https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.htmlid=168515"
X Link 2024-05-13T17:49Z [---] followers, [---] engagements
"@DrJulieVose discusses her upcoming ASCO presentation on #epcoritamab in R/R follicular lymphoma. #lymsm #ASCO24 $GMAB $ABBV #Genmab #AbbVie .@DrJulieVose discusses her upcoming @ASCO presentation on epcoritamab in R/R follicular lymphoma. #lymsm #ASCO24 To view our full conference coverage visit: https://t.co/1sfycf2uq1 https://t.co/wpegGZEb0g .@DrJulieVose discusses her upcoming @ASCO presentation on epcoritamab in R/R follicular lymphoma. #lymsm #ASCO24 To view our full conference coverage visit: https://t.co/1sfycf2uq1 https://t.co/wpegGZEb0g"
X Link 2024-05-30T11:10Z [---] followers, [---] engagements
"#Tisotumab vedotin #Tivdak #Genmab #Pfizer $GMAB $PFE Recurrent cervical cancer has a poor prognosis. The median overall survival was nearly [--] year with tisotumab vedotin an antibodydrug conjugate as compared with [---] months with chemotherapy. Read the full trial results: https://t.co/WasnIRU8Dm https://t.co/Z6Q1y6VrXX Recurrent cervical cancer has a poor prognosis. The median overall survival was nearly [--] year with tisotumab vedotin an antibodydrug conjugate as compared with [---] months with chemotherapy. Read the full trial results: https://t.co/WasnIRU8Dm https://t.co/Z6Q1y6VrXX"
X Link 2024-07-04T08:28Z [---] followers, [---] engagements
"#TIVDAK (tisotumab vedotin-tftv) Mechanism of Action Cervical cancer ADC #Genmab #Pfizer $GMAB $PFE https://www.youtube.com/watchv=R1WxeM4751c https://www.youtube.com/watchv=R1WxeM4751c"
X Link 2024-07-12T10:01Z [---] followers, [---] engagements
"Bispecific antibody #Epkinly shows miraculous results in 3rd-line treatment of DLBCL' #Genmab #AbbVie $GMAB $ABBV #Epcoritamab https://www.koreabiomed.com/news/articleView.htmlidxno=24545 https://www.koreabiomed.com/news/articleView.htmlidxno=24545"
X Link 2024-07-15T07:46Z [---] followers, [----] engagements
"#Tivdak (Tisotumab Vedotin) Cervical cancer ADC #Genmab #Pfizer $GMAB $PFE Tivdak (Tisotumab Vedotin) for Recurrent Cervical Cancer Recurrent cervical cancer is a life-threatening disease with limited treatment options available when disease progression occurs after first-line combination therapy. For patients with recurrent cervical cancer limited https://t.co/oOzMi95jkY Tivdak (Tisotumab Vedotin) for Recurrent Cervical Cancer Recurrent cervical cancer is a life-threatening disease with limited treatment options available when disease progression occurs after first-line combination therapy."
X Link 2024-07-15T13:10Z [---] followers, [----] engagements
"New trial: SC Injected #Epcoritamab + Lenalidomide Tablets Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) #Genmab #AbbVie $GMAB $ABBV #Epkinly https://www.clinicaltrials.gov/study/NCT06508658 https://www.clinicaltrials.gov/study/NCT06508658"
X Link 2024-07-18T13:25Z [---] followers, [---] engagements
"#Epcoritamab vs SoC (SCHOLAR-5 cohort) in patients with R/R FL #Genmab #AbbVie $GMAB $ABBV #Epkinly via @YouTube https://youtu.be/SQgjUgIJU4Efeature=shared https://youtu.be/SQgjUgIJU4Efeature=shared"
X Link 2024-07-23T07:14Z [---] followers, [---] engagements
"#AbbVie's #EPKINLY Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency #Genmab $ABBV $GMAB #Epcoritamab https://prn.to/46d212J https://prn.to/46d212J"
X Link 2024-07-23T11:19Z [---] followers, [---] engagements
"#EMA CHMP recommends #RYBREVANT (#amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy $JNJ $GMAB #Genmab https://www.globenewswire.com/en/news-release/2024/07/26/2919538/0/en/CHMP-recommends-RYBREVANT-amivantamab-in-combination-with-chemotherapy-for-the-treatment-of-adult-patients-with-advanced-EGFR-mutated-non-small-cell-lung-cancer-NSCLC-after-failure.html"
X Link 2024-07-26T12:57Z [---] followers, [---] engagements
"#DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible - PERSEUS $JNJ $GMAB #Genmab https://www.jnj.com/media-center/press-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-regimen-approved-in-the-u-s-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible"
X Link 2024-07-31T12:21Z [---] followers, [---] engagements
"Amgen's marketing efforts help boost #Tepezza sales #Teprotumumab $AMGN $GMAB #Genmab #Royalties https://www.fiercepharma.com/pharma/amgens-marketing-efforts-help-boost-tepezza-sales https://www.fiercepharma.com/pharma/amgens-marketing-efforts-help-boost-tepezza-sales"
X Link 2024-08-08T06:32Z [---] followers, [----] engagements
"#Epcoritamab Optimization Lowers Neurotoxicity Boosts Outpatient Feasibility in Follicular Lymphoma $GMAB $ABBV #Genmab #AbbVie #Epkinly via @onclive https://www.onclive.com/view/epcoritamab-optimization-lowers-neurotoxicity-boosts-outpatient-feasibility-in-follicular-lymphoma https://www.onclive.com/view/epcoritamab-optimization-lowers-neurotoxicity-boosts-outpatient-feasibility-in-follicular-lymphoma"
X Link 2024-08-08T07:10Z [---] followers, [----] engagements
"Comparisons of treatment outcomes of #epcoritamab versus chemoimmunotherapy polatuzumab-based regimens tafasitamab-based regimens or CAR T-cell therapy in 3rd-line or later relapsed/refractory large B-cell lymphoma $GMAB $ABBV #Genmab #AbbVie #Epkinly https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01594-x#citeas https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01594-x#citeas"
X Link 2024-08-19T06:45Z [---] followers, [----] engagements
"#RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. $JNJ $GMAB #Genmab #Royalties https://prn.to/3YToY9y https://prn.to/3YToY9y"
X Link 2024-08-20T11:25Z [---] followers, [---] engagements
"FDA Approval Alert: #Epcoritamab in Relapsed/Refractory Follicular Lymphoma $GMAB $ABBV #Genmab #AbbVie #Epkinly via @@CancerNetwrk https://www.cancernetwork.com/view/fda-approval-alert-epcoritamab-in-relapsed-refractory-follicular-lymphoma https://www.cancernetwork.com/view/fda-approval-alert-epcoritamab-in-relapsed-refractory-follicular-lymphoma"
X Link 2024-08-23T13:15Z [---] followers, [----] engagements
"$GMAB $ABBV #Genmab #AbbVie #Epcoritamab #Epkinly CONGRESS POSTER #SOHO2024 Yasmin Karimi @Yhkarimi presents extended follow-up data beyond [---] years from the pivotal expansion cohort of the phase II EPCORE NHL-1 study of epcoritamab monotherapy in R/R #DLBCL (N=157). Of pts with a CR (n=65) 54% remained in CR at [--] https://t.co/mkTvkPIput CONGRESS POSTER #SOHO2024 Yasmin Karimi @Yhkarimi presents extended follow-up data beyond [---] years from the pivotal expansion cohort of the phase II EPCORE NHL-1 study of epcoritamab monotherapy in R/R #DLBCL (N=157). Of pts with a CR (n=65) 54% remained"
X Link 2024-09-04T12:35Z [---] followers, [---] engagements
"#ESMO24: #Genmab Has AbbVie In Its Sights As Rina-S Shines In Ovarian Cancer - $GMAB Rinatabart Sesutecan http://scrip.citeline.com/articles/2024/09/16/esmo-24-genmab-has-abbvie-in-its-sights-as-rina-s-shines-in-ovarian-cancer http://scrip.citeline.com/articles/2024/09/16/esmo-24-genmab-has-abbvie-in-its-sights-as-rina-s-shines-in-ovarian-cancer"
X Link 2024-09-17T08:15Z [---] followers, [---] engagements
"$GMAB $ABBV #Genmab #AbbVie #Epcoritamab #Epkinly In this episode of #OncLiveOnAir @JenCrombieMD of @DanaFarber shares insights about the @US_FDA approval of epcoritamab for patients with relapsed/refractory follicular #lymphoma. #lymsm #oncology https://t.co/b0H9YnBeYu https://t.co/PKQrMyGQL3 In this episode of #OncLiveOnAir @JenCrombieMD of @DanaFarber shares insights about the @US_FDA approval of epcoritamab for patients with relapsed/refractory follicular #lymphoma. #lymsm #oncology https://t.co/b0H9YnBeYu https://t.co/PKQrMyGQL3"
X Link 2024-09-17T11:47Z [---] followers, [----] engagements
"New #Novartis data in relapsing MS reinforce benefits of #Kesimpta for first-line and switch patients $NVS $GMAB #Genmab https://www.novartis.com/news/media-releases/new-novartis-data-relapsing-ms-reinforce-benefits-kesimpta-first-line-and-switch-patients https://www.novartis.com/news/media-releases/new-novartis-data-relapsing-ms-reinforce-benefits-kesimpta-first-line-and-switch-patients"
X Link 2024-09-18T07:53Z [---] followers, [---] engagements
"#RYBREVANT (#amivantamab-vmjw) plus standard of care #approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer $JNJ $GMAB #Genmab #Royalties https://prn.to/3XQ5otI https://prn.to/3XQ5otI"
X Link 2024-09-20T06:46Z [---] followers, [---] engagements
"#Tepezza (Teprotumumab) Receives Approval in #Japan for the Treatment of Active Thyroid Eye Disease $AMGN #Genmab $GMAB #Royalties https://prn.to/4efprYf https://prn.to/4efprYf"
X Link 2024-09-25T06:26Z [---] followers, [---] engagements
"$JNJ $GMAB #Genmab #Darzalex #Daratumumab CONGRESS #IMS2024 PRESENTATION Jill Corre shares an MRD update from the phase III CASSIOPEIA trial (N = 1085) which established D-VTd as a standard of care for transplant eligible NDMM. Extended follow-up demonstrated that DARA-based induction/consolidation and maintenance https://t.co/7tfJIewuYY CONGRESS #IMS2024 PRESENTATION Jill Corre shares an MRD update from the phase III CASSIOPEIA trial (N = 1085) which established D-VTd as a standard of care for transplant eligible NDMM. Extended follow-up demonstrated that DARA-based induction/consolidation"
X Link 2024-09-26T10:50Z [---] followers, [----] engagements
"$JNJ $GMAB #Genmab #Darzalex #Daratumumab CONGRESS #IMS2024 PRESENTATION Meletios Dimopoulos @thanosdimop shares findings from a cytogenetic risk analysis of the phase III PERSEUS trial (N = 709) which demonstrated a significant PFS benefit for the addition of daratumumab (D) to VRd induction and consolidation https://t.co/42G8mmVmPt CONGRESS #IMS2024 PRESENTATION Meletios Dimopoulos @thanosdimop shares findings from a cytogenetic risk analysis of the phase III PERSEUS trial (N = 709) which demonstrated a significant PFS benefit for the addition of daratumumab (D) to VRd induction and"
X Link 2024-09-26T11:59Z [---] followers, [----] engagements
"#Epcoritamab in R/R large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial 'deep responses across subgroups including patients with hard-to-treat disease and expected poor prognosis' #Genmab $GMAB #AbbVie $ABBV #Epkinly https://www.nature.com/articles/s41375-024-02410-8 https://www.nature.com/articles/s41375-024-02410-8"
X Link 2024-09-27T11:40Z [---] followers, [---] engagements
"Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on #Tisotumab Vedotin state of art - Therapeutic Advances in Medical Oncology #Tivdak $GMAB $PFE #Genmab #Pfizer https://journals.sagepub.com/doi/10.1177/17588359241277647 https://journals.sagepub.com/doi/10.1177/17588359241277647"
X Link 2024-09-30T11:30Z [---] followers, [---] engagements
"Johnson & Johnson files for U.S. FDA approval of #DARZALEX FASPRO-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned #CEPHEUS $JNJ $GMAB #genmab https://prn.to/3Bu49aX https://prn.to/3Bu49aX"
X Link 2024-10-01T06:52Z [---] followers, [---] engagements
"🎧 Listen to Dr Ignace Vergote discuss: #Tisotumab Vedotin in Second- & Third-Line Recurrent CervicalCancer #Genmab #Pfizer $GMAB $PFE #Tivdak #WeeklyPodcast 🎧 Listen to Dr Ignace Vergote discuss #Tisotumab Vidotin in Second- & Third-Line #Recurrent #CervicalCancer @ https://t.co/BxuLB6RB9L @pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 https://t.co/z59mvKdglG #WeeklyPodcast 🎧 Listen to Dr Ignace Vergote discuss #Tisotumab Vidotin in Second- & Third-Line #Recurrent #CervicalCancer @ https://t.co/BxuLB6RB9L"
X Link 2024-10-09T07:27Z [---] followers, [----] engagements
"Hemab is using #Genmab's DuoBody technology. Hemab Therapeutics is actively enrolling a Phase [--] clinical trial of HMB-001 a subcutaneous injection designed to restore clot formation impaired by Glanzmann Thrombasthenia. $GMAB $NOVO For those living with Glanzmann Thrombasthenia (GT) there is no time to wait. Over a century since GT was first described treatment options remain limited. GT is a severe bleeding disorder that limits blood's ability to clot presenting constant challengesfrom frequent https://t.co/ca5ta5LFGM For those living with Glanzmann Thrombasthenia (GT) there is no time to"
X Link 2024-10-09T11:42Z [---] followers, [----] engagements
"Johnson & Johnson submits application to the European Medicines Agency for DARZALEX (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patients #EMA D-VRd CEPHEUS $JNJ $GMAB #Genmab https://www.globenewswire.com/news-release/2024/10/10/2961071/0/en/Johnson-Johnson-submits-application-to-the-European-Medicines-Agency-for-DARZALEX-daratumumab-SC-based-quadruplet-regimen-for-newly-diagnosed-multiple-myeloma-patients.html"
X Link 2024-10-10T09:55Z [---] followers, [---] engagements
"Patients thrown lifeline after NICE lifts restrictions on game-changing treatment #Teclistamab $JNJ $GMAB #Genmab #Tecvayli https://www.myeloma.org.uk/news/patients-thrown-lifeline-after-nice-lifts-restrictions-on-game-changing-treatment/ https://www.myeloma.org.uk/news/patients-thrown-lifeline-after-nice-lifts-restrictions-on-game-changing-treatment/"
X Link 2024-10-11T06:32Z [---] followers, [---] engagements
"#DARZALEX (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible #PERSEUS #EMA $JNJ $GMAB #Genmab https://www.globenewswire.com/news-release/2024/10/23/2967491/0/en/DARZALEX-daratumumab-SC-based-quadruplet-regimen-approved-by-the-European-Commission-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible.html"
X Link 2024-10-23T08:46Z [---] followers, [---] engagements
"#Tisotumab Vedotin vs Chemo in Japanese Patients With R/M Cervical Cancer -innovaTV [---] #JSCO2024 During the median follow-up period of [----] months the median OS was 15.0m in the TV group vs 8.5m in the chemotherapy group #Tivdak #Genmab $GMAB $PFE https://medical.nikkeibp.co.jp/leaf/all/cancernavi/news/202410/586322.html https://medical.nikkeibp.co.jp/leaf/all/cancernavi/news/202410/586322.html"
X Link 2024-10-30T13:41Z [---] followers, [---] engagements
"last years ESMO data showed median OS [----] mo vs [---] mo (after median survival follow-up [----] mo) so is the improvement only in Japanese patients or does it have anything to do with improved toxicity management #Genmab $GMAB $PFE #Pfizer https://oncologypro.esmo.org/meeting-resources/esmo-congress-2023/innovatv-301-engot-cx12-gog-3057-a-global-randomized-open-label-phase-iii-study-of-tisotumab-vedotin-vs-investigator-s-choice-of-chemotherapy-i"
X Link 2024-10-30T13:56Z [---] followers, [---] engagements
"@IJGConline the Japanese Society of Clinical Oncology meeting shows much better data Any explanation During the median follow-up of [----] months median OS was 15.0mo in the #Tisotumab Vedotin group vs 8.5mo in the chemo group (was [----] vs 9.5) $GMAB $PFE @Genmab https://medical.nikkeibp.co.jp/leaf/all/cancernavi/news/202410/586322.html https://medical.nikkeibp.co.jp/leaf/all/cancernavi/news/202410/586322.html"
X Link 2024-10-31T12:36Z [---] followers, [---] engagements
"Drugs for unmet needs and those from experienced companies had the best chance for successful launches in [----] '#Genmab and #AbbVies debut of #Epkinly for patients with DLBCL has also exceeded expectations in its battle with Roche's Columvi.' https://www.fiercepharma.com/pharma/drugs-unmet-needs-and-those-experienced-companies-have-best-chance-successful-launches https://www.fiercepharma.com/pharma/drugs-unmet-needs-and-those-experienced-companies-have-best-chance-successful-launches"
X Link 2024-11-07T12:08Z [---] followers, [---] engagements
"CHMP adopted a positive opinion on the marketing authorisation for #Rybrevant. #EMA (MARIPOSA) $JNJ $GMAB #Genmab #amivantamab"
X Link 2024-11-15T15:19Z [---] followers, [---] engagements
"@Chris_Whittall and wouldn't the increased use of margin agreements in the swap markets also be a factor as it mitigates the counterparty risk and thus credit spread"
X Link 2024-11-18T10:19Z [---] followers, [--] engagements
"Teprotumumab / Tepezza $AMGN $GMAB #Amgen #Genmab The FDA approved Tepezza in [----] for treating TED following promising results from clinical trials. The results of [--] recent real-world studies show encouraging outcomes and indicate that the drug is performing well for a high percentage of patients https://t.co/8AAs8vwn9g https://t.co/WAFLmmuj3o The FDA approved Tepezza in [----] for treating TED following promising results from clinical trials. The results of [--] recent real-world studies show encouraging outcomes and indicate that the drug is performing well for a high percentage of patients"
X Link 2024-11-18T14:00Z [---] followers, [----] engagements
"Novartis upgrades #Kesimpta peak sales estimates to $6bn $NOVN $NVS $GMAB #Genmab #Royalties #ofatumumab"
X Link 2024-11-21T11:29Z [---] followers, [----] engagements
"@BertrandBio Ipsen sold one for $158m last summer and I think AbbVie once bought one for $350m many years ago. Deflation 😁Don't tell Trump he'll claim it as his success 😆 It seems the Pediatric PRV's are worth more"
X Link 2024-11-27T12:33Z [---] followers, [--] engagements
"the addition of #daratumumab (darzalex) to VRd significantly increased MRD negativity rates compared to VRd alone in transplant-ineligible patients $JNJ $GMAB #Genmab via @@Pharmacy_Times https://www.pharmacytimes.com/view/ash-2024-expert-highlights-bolstered-mrd-negativity-with-daratumumab-vrd-in-multiple-myeloma https://www.pharmacytimes.com/view/ash-2024-expert-highlights-bolstered-mrd-negativity-with-daratumumab-vrd-in-multiple-myeloma"
X Link 2024-12-11T15:40Z [---] followers, [---] engagements
"#Genmab #AbbVie $GMAB $ABBV #Epcoritamab #Epkinly #CLL Promising results for heavily pretreated #CLL #Epcoritamab achieved 39% complete response & 75% uMRD in the EPCORE CLL-1 trial. Optimized dosing reduced severe CRS & #Neurotoxicity. https://t.co/iLCq9IZYuq #CLLSM #Hematology #ASH24 @DanilovLab Promising results for heavily pretreated #CLL #Epcoritamab achieved 39% complete response & 75% uMRD in the EPCORE CLL-1 trial. Optimized dosing reduced severe CRS & #Neurotoxicity. https://t.co/iLCq9IZYuq #CLLSM #Hematology #ASH24 @DanilovLab"
X Link 2024-12-12T09:41Z [---] followers, [----] engagements
"Essential material for both @Genmab and #AbbVie investors [----] R&D Update and ASH Data Review webcast replay and supporting presentations via: $GMAB $ABBV $ROG $RHHBY #Epkinly #Epcoritamab #Rina-S https://ir.genmab.com/events-presentations https://ir.genmab.com/events-presentations"
X Link 2024-12-13T13:32Z [---] followers, [---] engagements
"@amandagarces @statnews @angRchen it's not just AbbVie it's 50/50 partnered with Genmab"
X Link 2024-12-13T14:59Z [---] followers, [---] engagements
"Tivdak officially launched in Hong Kong and Macao #Tisotumab Vedotin $GMAB #Genmab $PFE #Pfizer #Zailab https://finance.china.com.cn/industry/medicine/20241216/6197105.shtml https://finance.china.com.cn/industry/medicine/20241216/6197105.shtml"
X Link 2024-12-16T14:31Z [---] followers, [---] engagements
"#Kempen raises target price for #Genmab to DKK [----] (2650) reiterates #Buy $GMAB BN #MarketScreener https://www.marketscreener.com/quote/stock/GENMAB-A-S-63733191/news/Kempen-raises-target-price-for-Genmab-to-DKK-2-950-2-650-reiterates-Buy-BN-48616994/utm_source=twitter&utm_medium=social&utm_campaign=share https://www.marketscreener.com/quote/stock/GENMAB-A-S-63733191/news/Kempen-raises-target-price-for-Genmab-to-DKK-2-950-2-650-reiterates-Buy-BN-48616994/utm_source=twitter&utm_medium=social&utm_campaign=share"
X Link 2024-12-19T09:30Z [---] followers, [---] engagements
"European Commission approves #RYBREVANT (#amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer - MARIPOSA $JNJ $GMAB #Genmab #EMA https://www.globenewswire.com/news-release/2024/12/30/3002463/0/en/European-Commission-approves-RYBREVANT-amivantamab-in-combination-with-LAZCLUZE-lazertinib-for-the-first-line-treatment-of-patients-with-EGFR-mutated-advanced-non-small-cell-lung-c.html"
X Link 2024-12-30T08:56Z [---] followers, [----] engagements
"@PCM_bio @LuciusJameson @john_bresnahan JNJ is currently reviewing a possible follow up to Darzalex; Hexabody-CD38 or Erzotabart is also developed by Genmab. Decision to opt-in to this 'SuperDara' or not is anticipated somewhere before the end of March"
X Link 2025-01-06T17:17Z [---] followers, [---] engagements
"#Rybrevant $JNJ $GMAB #Genmab Amivantamab #BREAKING: Topline results for the key secondary endpoint of overall survival from the Phase [--] MARIPOSA study highlight treatment progress for patients with EGFR-mutated #NSCLC: https://t.co/l3tpGs7VJT #JNJOncology https://t.co/5nP7vLEADm #BREAKING: Topline results for the key secondary endpoint of overall survival from the Phase [--] MARIPOSA study highlight treatment progress for patients with EGFR-mutated #NSCLC: https://t.co/l3tpGs7VJT #JNJOncology https://t.co/5nP7vLEADm"
X Link 2025-01-07T13:51Z [---] followers, [----] engagements
"$GMAB $ABBV #Genmab #AbbVie #Epcoritamab #Epkinly #Hematology Impressive results of #epcoritamab + GEMOX in transplant ineligible R/R DLBCL patients with ORR/CR 85%/61% and even better if given in 2L with ORR/CR 90/74% #lymsm https://t.co/ZoVaYCUaDz #Hematology Impressive results of #epcoritamab + GEMOX in transplant ineligible R/R DLBCL patients with ORR/CR 85%/61% and even better if given in 2L with ORR/CR 90/74% #lymsm https://t.co/ZoVaYCUaDz"
X Link 2025-01-13T09:50Z [---] followers, [----] engagements
"European Commission approves LAZCLUZE (lazertinib) in combination with #RYBREVANT (#amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer $JNJ $GMAB #Genmab #EMA #NSCLC https://finance.yahoo.com/news/european-commission-approves-lazcluze-lazertinib-083000278.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr https://finance.yahoo.com/news/european-commission-approves-lazcluze-lazertinib-083000278.htmlsoc_src=social-sh&soc_trk=tw&tsrc=twtr"
X Link 2025-01-21T09:54Z [---] followers, [----] engagements
"@Mylovanov [--------] lives not even close even when you include Spain which apparently is now part of BRICS 😂"
X Link 2025-01-22T16:38Z [---] followers, [---] engagements
"'Enhancing complement activation by therapeutic anti-tumor antibodies' Focus on hexamerization & publication date March [----]. What other Hexabody news in March [--] could this be aligned with🤔😄 #Hexabody-CD38 #Erzotabart @Genmab $GMAB $JNJ #SuperDara https://www.sciencedirect.com/science/article/pii/S1044532324000605 https://www.sciencedirect.com/science/article/pii/S1044532324000605"
X Link 2025-01-29T10:16Z [---] followers, [---] engagements
"BMO Capital maintained #Genmab A/S ( $GMAB ) coverage with #Outperform and target $47 Past Target Price: $48"
X Link 2025-01-29T14:00Z [---] followers, [---] engagements
"Novartis #Kesimpta Q4 '24 $950mn FY '24 $3224mn (=+49%) #Genmab $GMAB #Ofatumumab #Royalties 10%"
X Link 2025-01-31T07:19Z [---] followers, [---] engagements
"#Tivdak(tisotumab vedotin) received a positive opinion from the #CHMP for the treatment of recurrent or metastatic cervical cancer. #Genmab #Pfizer $GMAB $PFE #EMA"
X Link 2025-01-31T11:13Z [---] followers, [---] engagements
"#Tisotumab Vedotin Grnes Licht fr neue Option bei Zervixkarzinom #Genmab #Pfizer $GMAB $PFE #Tivdak https://www.pharmazeutische-zeitung.de/gruenes-licht-fuer-neue-option-bei-zervixkarzinom-152890/ https://www.pharmazeutische-zeitung.de/gruenes-licht-fuer-neue-option-bei-zervixkarzinom-152890/"
X Link 2025-02-01T09:41Z [---] followers, [---] engagements
"Hemab is using #Genmab's DuoBody technology $GMAB $NOVO NEWS: Today at #EAHAD2025 we presented interim data from the ongoing Phase [--] study of HMB-001 designed to be the first ever prophylactic treatment for Glanzmann thrombasthenia as well as promising HMB-002 preclinical data for Von Willebrand Disease. HIGHLIGHTS: Interim https://t.co/W2tmMS3yRm NEWS: Today at #EAHAD2025 we presented interim data from the ongoing Phase [--] study of HMB-001 designed to be the first ever prophylactic treatment for Glanzmann thrombasthenia as well as promising HMB-002 preclinical data for Von Willebrand Disease."
X Link 2025-02-07T15:54Z [---] followers, [---] engagements
"#EPKINLY (epcoritamab) Approved by #Japan Ministry of Health Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory #Follicular Lymphoma $GMAB $ABBV #Genmab #AbbVie https://www.globenewswire.com/news-release/2025/02/20/3029562/0/en/EPKINLY-epcoritamab-Approved-by-Japan-Ministry-of-Health-Labour-and-Welfare-for-Additional-Indication-as-a-Treatment-for-Relapsed-or-Refractory-Follicular-Lymphoma.html"
X Link 2025-02-20T13:46Z [---] followers, [---] engagements
"#Genmab reports promising data in ovarian cancer treatment study - Rina-S $GMAB #Rinatabart Sesutecan https://medwatch.com/News/Pharma___Biotech/article18004885.ece https://medwatch.com/News/Pharma___Biotech/article18004885.ece"
X Link 2025-03-18T07:45Z [---] followers, [----] engagements
"#SGOMtg [----] Genmabs advantage looks Profound $GMAB Rina-S #Rinatabart Sesutecan https://www.oncologypipeline.com/apexonco/sgo-2025-genmabs-advantage-looks-profound https://www.oncologypipeline.com/apexonco/sgo-2025-genmabs-advantage-looks-profound"
X Link 2025-03-19T07:51Z [---] followers, [---] engagements
"#Genmab $GMAB Rina-S #Rinatabart Sesutecan #SGOMtg [----] 6:30 AM on a Saturday in #Rome: Regina Berger Stephan Polterauer & Christian Marth at the Investigator Meeting for the Phase III trial RAINFOL-OV2. 🔬 Testing Rinatabart Sesutecan (Rina-S) for platinum-resistant #OvarianCancer. 💙 #AGOAustria leading as the #ENGOT study group. https://t.co/6cgbOP4zmm 6:30 AM on a Saturday in #Rome: Regina Berger Stephan Polterauer & Christian Marth at the Investigator Meeting for the Phase III trial RAINFOL-OV2. 🔬 Testing Rinatabart Sesutecan (Rina-S) for platinum-resistant #OvarianCancer. 💙"
X Link 2025-03-19T07:53Z [---] followers, [---] engagements
"#Genmab Announces Initiation of Share Buy-Back Program $GMAB https://ir.genmab.com/news-releases/news-release-details/genmab-announces-initiation-share-buy-back-program-4 https://ir.genmab.com/news-releases/news-release-details/genmab-announces-initiation-share-buy-back-program-4"
X Link 2025-03-26T06:47Z [---] followers, [---] engagements
"#TIVDAK (tisotumab vedotin) Approved by #Japan Ministry of Health Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy Big market for Cervical cancer. $GMAB $PFE #Pfizer https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-japan-ministry-health-labour https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-japan-ministry-health-labour"
X Link 2025-03-27T12:20Z [---] followers, [---] engagements
"#TIVDAK (tisotumab vedotin) Approved by #European Commission for Previously Treated Recurrent or Metastatic #Cervical Cancer #Genmab $GMAB #Pfizer $PFE #EMA https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-european-commission https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-european-commission"
X Link 2025-03-31T17:26Z [---] followers, [---] engagements
"@fyee0308 @davidmygind $GMAB #Genmab https://www.linkedin.com/posts/mygind-management_biotechanalysis-genmab-precisionmedicine-activity-7311027431589498880-ppKxutm_medium=ios_app&rcm=ACoAAACIYqABSM5yt5vwlKC7IlzfrJTkl7kbQNo&utm_source=social_share_send&utm_campaign=copy_link https://www.linkedin.com/posts/mygind-management_biotechanalysis-genmab-precisionmedicine-activity-7311027431589498880-ppKxutm_medium=ios_app&rcm=ACoAAACIYqABSM5yt5vwlKC7IlzfrJTkl7kbQNo&utm_source=social_share_send&utm_campaign=copy_link"
X Link 2025-03-31T17:58Z [---] followers, [--] engagements
"New Chromatography Data Platform Wins Bio-IT World Award for Genmab $GMAB and Genedata "Genmab seeks to integrate AI into everything we do and we are continuously looking for ways that AI can address operational challenges" https://prn.to/4cftzY4 https://prn.to/4cftzY4"
X Link 2025-04-04T12:52Z [---] followers, [---] engagements
"European Commission approves #subcutaneous #RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer $JNJ $GMAB #Genmab #EMA https://www.globenewswire.com/news-release/2025/04/07/3056770/0/en/European-Commission-approves-subcutaneous-RYBREVANT-amivantamab-for-the-treatment-of-patients-with-advanced-EGFR-mutated-non-small-cell-lung-cancer.html"
X Link 2025-04-07T13:34Z [---] followers, [---] engagements
"#Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial $GMAB $ABBV #Genmab #AbbVie #Epkinly https://ashpublications.org/blood/article/doi/10.1182/blood.2024026830/535030/Epcoritamab-plus-GemOx-in-transplant-ineligible https://ashpublications.org/blood/article/doi/10.1182/blood.2024026830/535030/Epcoritamab-plus-GemOx-in-transplant-ineligible"
X Link 2025-04-11T06:46Z [---] followers, [---] engagements
"#Genmab $GMAB Rinatabart Sesutecan #GEN1184 📽 Tune into our video with Dr. Elizabeth K. Lee (@EKLee_MD) of @danafarber as she discusses treatment with with Rina-S; the agent showed antitumor activity in heavily pretreated patients with advanced #OvarianCancer. #MedEd 👉 Watch the video here: https://t.co/gNg68GwOV4 📽 Tune into our video with Dr. Elizabeth K. Lee (@EKLee_MD) of @danafarber as she discusses treatment with with Rina-S; the agent showed antitumor activity in heavily pretreated patients with advanced #OvarianCancer. #MedEd 👉 Watch the video here: https://t.co/gNg68GwOV4"
X Link 2025-04-15T12:03Z [---] followers, [---] engagements
"#Genmab $GMAB Rina-S #Rinatabart Sesutecan Elizabeth K. Lee MD of @DanaFarber discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer. @EKLee_MD Read the full article here: https://t.co/gHRh4xpMWa https://t.co/tGpSvxABpz Elizabeth K. Lee MD of @DanaFarber discusses data from the phase 1/2 RAINFOL-01 study of Rina-S in advanced ovarian cancer. @EKLee_MD Read the full article here: https://t.co/gHRh4xpMWa https://t.co/tGpSvxABpz"
X Link 2025-04-27T12:51Z [---] followers, [----] engagements
"#Tepezza (teprotumumab) received a positive opinion from the CHMP for the treatment of adults with moderate to severe Thyroid Eye Disease (TED) also known as Graves Eye Diseas $AMGN $GMAB #Amgen #Genmab #Royalties #EMA https://www.ema.europa.eu/en/medicines/human/EPAR/tepezza https://www.ema.europa.eu/en/medicines/human/EPAR/tepezza"
X Link 2025-04-28T05:57Z [---] followers, [---] engagements
"Tepezza $AMGN $GMAB #Amgen #Genmab"
X Link 2025-04-29T11:29Z [---] followers, [--] engagements
"#Amgens #TEPEZZA (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom $AMGN $GMAB #Genmab https://www.businesswire.com/news/home/20250507246547/en/Amgens-TEPEZZA-teprotumumab-Granted-Marketing-Authorisation-as-the-First-Targeted-Treatment-Specifically-for-Adults-With-Moderate-to-severe-Thyroid-Eye-Disease-TED-in-the-United-Kingdomutm_campaign=shareaholic&utm_medium=twitter&utm_source=socialnetwork"
X Link 2025-05-07T18:16Z [---] followers, [---] engagements
"@BertrandBio it is exactly one of the points Genmab's Jan van de Winkel made when promoting Hexabody-CD38 in one of his conference calls; wouldn't it be fun if JNJ were to reconsider their decision to opt-out of Hexa-CD38 😂"
X Link 2025-05-14T17:13Z [---] followers, [---] engagements
"VIDEO: Response seen with Rina-S in ovarian cancer despite FR-alpha expression levels $GMAB #Genmab #Rinatabart Sesutecan https://www.healio.com/news/hematology-oncology/20250514/video-response-seen-with-rina-s-in-ovarian-cancer-despite-fr-alpha-expression-levelsutm_medium=social&utm_source=twitter&utm_campaign=sociallinks https://www.healio.com/news/hematology-oncology/20250514/video-response-seen-with-rina-s-in-ovarian-cancer-despite-fr-alpha-expression-levelsutm_medium=social&utm_source=twitter&utm_campaign=sociallinks"
X Link 2025-05-15T07:59Z [---] followers, [---] engagements
"#Rinatabart sesutecan (Rina-S) for patients with advanced #endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study. @Genmab $GMAB #ASCO25 https://meetings.asco.org/abstracts-presentations/246292 https://meetings.asco.org/abstracts-presentations/246292"
X Link 2025-05-23T09:45Z [---] followers, [---] engagements
"#Rinatabart sesutecan (Rina-S) #endometrial cancer @Genmab $GMAB #ASCO25 $GMAB - Endometrial cancer data on Genmabs Elahere rival beat forecast fuelling push into phase [--] - https://t.co/V2dQZxjW9m $GMAB - Endometrial cancer data on Genmabs Elahere rival beat forecast fuelling push into phase [--] - https://t.co/V2dQZxjW9m"
X Link 2025-05-23T13:44Z [---] followers, [----] engagements
"@Genmab $GMAB #AbbVie $ABBV #Epkinly #epcoritamab #ASCO25 CONGRESS #ASCO25 PRESENTATION @DrJulieVose @unmc @NebraskaMed shares insights on incorporating epcoritamab into clinical practice for the treatment of patients with R/R FL. They highlight results from the pivotal FL cohort of the EPCORE NHL-1 trial (N = 128) and discuss key https://t.co/kKgeGYjdzB CONGRESS #ASCO25 PRESENTATION @DrJulieVose @unmc @NebraskaMed shares insights on incorporating epcoritamab into clinical practice for the treatment of patients with R/R FL. They highlight results from the pivotal FL cohort of the EPCORE NHL-1"
X Link 2025-05-31T07:38Z [---] followers, [---] engagements
"@Genmab $GMAB #AbbVie $ABBV #Epkinly #epcoritamab #ASCO25 CONGRESS #ASCO25 POSTER Yasmin Karimi @Yhkarimi @UMich shares 3-year data from the pivotal EPCORE NHL-1 study of a subgroup of pts with R/R LBCL and CR at [--] years with epcoritamab monotherapy. About 96% of patients were still at CR at [--] years. Median DoCR PFS and OS not https://t.co/im8mxB0a9N CONGRESS #ASCO25 POSTER Yasmin Karimi @Yhkarimi @UMich shares 3-year data from the pivotal EPCORE NHL-1 study of a subgroup of pts with R/R LBCL and CR at [--] years with epcoritamab monotherapy. About 96% of patients were still at CR at [--] years."
X Link 2025-06-01T18:03Z [---] followers, [---] engagements
"#Genmab $GMAB #AbbVie $ABBV #Epkinly #epcoritamab #ASCO25 Two years after starting treatment with epcoritamab a subgroup of patients with relapsed or refractory #LBCL are showing long-term disease remission and overall survival according to post-hoc analysis data from EPCORE-NHL-1 presented at #ASCO25. 📰 https://t.co/TWvEirsH4w https://t.co/PgsxLyO8db Two years after starting treatment with epcoritamab a subgroup of patients with relapsed or refractory #LBCL are showing long-term disease remission and overall survival according to post-hoc analysis data from EPCORE-NHL-1 presented at"
X Link 2025-06-03T07:51Z [---] followers, [---] engagements
"#ASCO25: #Genmabs #Rina-S en route to blockbuster potential amid further positive data $GMAB #rinatabart sesutecan via @TrialsArena https://www.clinicaltrialsarena.com/news/asco25-genmabs-rina-s-en-route-to-blockbuster-potential-amid-further-positive-data/ https://www.clinicaltrialsarena.com/news/asco25-genmabs-rina-s-en-route-to-blockbuster-potential-amid-further-positive-data/"
X Link 2025-06-03T12:21Z [---] followers, [---] engagements
"#Genmab $GMAB #Epkinly"
X Link 2025-06-17T18:17Z [---] followers, [--] engagements
"EHA [----] J&J claims an extramedullary edge $JNJ $GMAB #Genmab #Talvey #Tecvayli https://www.oncologypipeline.com/apexonco/eha-2025-jj-claims-extramedullary-edge https://www.oncologypipeline.com/apexonco/eha-2025-jj-claims-extramedullary-edge"
X Link 2025-06-18T05:31Z [---] followers, [---] engagements
"#Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant #Genmab $GMAB #AbbVie $ABBV #Epkinly #EHA2025 via @AJMC https://www.ajmc.com/view/epcoritamab-plus-chemoimmunotherapy-yields-87-response-rate-in-r-r-dlbcl-65-proceed-to-transplant https://www.ajmc.com/view/epcoritamab-plus-chemoimmunotherapy-yields-87-response-rate-in-r-r-dlbcl-65-proceed-to-transplant"
X Link 2025-06-18T05:36Z [---] followers, [---] engagements
"RITUXIMAB AND #EPCORITAMAB AS #FIRST-LINE THERAPY FOR PATIENTS WITH HIGH-TUMOR BURDEN #FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIAL #Genmab $GMAB #AbbVie $ABBV #Epkinly #icml2025 https://onlinelibrary.wiley.com/doi/10.1002/hon.70094_227 https://onlinelibrary.wiley.com/doi/10.1002/hon.70094_227"
X Link 2025-06-18T12:40Z [---] followers, [---] engagements
"Results from EPCORE NHL-2 trial of #epcoritamab + R-CHOP for previously untreated DLBCL #Genmab $GMAB #AbbVie $ABBV #Epkinly #ICML2025 https://youtu.be/9sco80a47i4feature=shared https://youtu.be/9sco80a47i4feature=shared"
X Link 2025-06-19T09:06Z [---] followers, [----] engagements
"#Genmab $GMAB #AbbVie $ABBV #Epcoritamab #Epkinly #ICML2025 Bispecifics in the frontline In EPCORE NHL-5 Epcoritamab + pola-R-CHP in 1L DLBCL: ORR 100% CRR 97% 81% MRD by C3D1 (ctDNA) Durable deep responses. No ICANS. All CRS low grade. #ICML2025 #18ICML #lymsm https://t.co/tXXGx3AnwJ Bispecifics in the frontline In EPCORE NHL-5 Epcoritamab + pola-R-CHP in 1L DLBCL: ORR 100% CRR 97% 81% MRD by C3D1 (ctDNA) Durable deep responses. No ICANS. All CRS low grade. #ICML2025 #18ICML #lymsm https://t.co/tXXGx3AnwJ"
X Link 2025-06-19T09:38Z [---] followers, [----] engagements
"#Genmab $GMAB #AbbVie $ABBV #Epcoritamab #Epkinly #ICML2025 Also: matched analysis of epco-R-miniCHOP vs R-miniCHOP shows 64% risk of progression and 80% risk of death. CR rate: 92.8% vs 67.1%. Small N but a strong signal. #18ICML #lymsm https://t.co/g4APilDqQB Also: matched analysis of epco-R-miniCHOP vs R-miniCHOP shows 64% risk of progression and 80% risk of death. CR rate: 92.8% vs 67.1%. Small N but a strong signal. #18ICML #lymsm https://t.co/g4APilDqQB"
X Link 2025-06-19T09:39Z [---] followers, [----] engagements
"#DARZALEX (daratumumab) receives the first positive #CHMP opinion for patients with high-risk #smouldering multiple myeloma $JNJ $GMAB #Genmab $HALO #EMA https://www.globenewswire.com/news-release/2025/06/20/3102621/0/en/DARZALEX-daratumumab-receives-the-first-positive-CHMP-opinion-for-patients-with-high-risk-smouldering-multiple-myeloma.html https://www.globenewswire.com/news-release/2025/06/20/3102621/0/en/DARZALEX-daratumumab-receives-the-first-positive-CHMP-opinion-for-patients-with-high-risk-smouldering-multiple-myeloma.html"
X Link 2025-06-20T10:42Z [---] followers, [---] engagements
"Phase III trial of #rinatabart sesutecan in platinum-resistant ovarian cancer #Genmab $GMAB Rina-S @AngelesSecord https://www.youtube.com/watchv=JSXmQpDA71M https://www.youtube.com/watchv=JSXmQpDA71M"
X Link 2025-07-08T08:30Z [---] followers, [---] engagements
"FDA rejects new indication for Columvi Roche Genentech $ABBV $GMAB AbbVie Genmab #Epkinly #Epcoritamab via @onclive https://www.onclive.com/view/fda-issues-crl-for-glofitamab-plus-chemo-in-r-r-dlbcl https://www.onclive.com/view/fda-issues-crl-for-glofitamab-plus-chemo-in-r-r-dlbcl"
X Link 2025-07-21T08:11Z [---] followers, [---] engagements
"Trial results set up AbbVie Genmab's Epkinly for key expansion in follicular lymphoma https://www.fiercehealthcare.com/pharma/new-results-set-abbvie-genmabs-epkinly-key-expansion-follicular-lymphoma https://www.fiercehealthcare.com/pharma/new-results-set-abbvie-genmabs-epkinly-key-expansion-follicular-lymphoma"
X Link 2025-08-11T18:41Z [---] followers, [---] engagements
"#Epkinly bucks the delay trend #Genmab #AbbVie $GMAB $ABBV https://www.oncologypipeline.com/apexonco/epkinly-bucks-delay-trend https://www.oncologypipeline.com/apexonco/epkinly-bucks-delay-trend"
X Link 2025-08-11T19:54Z [---] followers, [---] engagements
"#GENMAB : target price raised by UBS UBS confirms its "buy" recommendation on Genmab shares with a target price raised from [----] to [----] Danish kronor $GMAB #MarketScreener https://www.marketscreener.com/news/genmab-target-price-raised-by-ubs-ce7c51dbda8bf62dutm_source=twitter&utm_medium=social&utm_campaign=share https://www.marketscreener.com/news/genmab-target-price-raised-by-ubs-ce7c51dbda8bf62dutm_source=twitter&utm_medium=social&utm_campaign=share"
X Link 2025-08-13T09:23Z [---] followers, [----] engagements
"Outpatient #Epcoritamab Demonstrates Efficacy and Safety in R/R DLBCL $GMAB #Genmab via @targetedonc https://www.targetedonc.com/view/outpatient-epcoritamab-demonstrates-efficacy-and-safety-in-r-r-dlbcl https://www.targetedonc.com/view/outpatient-epcoritamab-demonstrates-efficacy-and-safety-in-r-r-dlbcl"
X Link 2025-09-04T14:44Z [---] followers, [---] engagements
"New Phase [--] trial: Study to Assess the Efficacy and Safety of #Rina-S Compared to Treatment of Investigator's Choice in Participants With #Endometrial Cancer (RAINFOL-03) @Genmab $GMAB #Rinatabart Sesutecan https://clinicaltrials.gov/study/NCT07166094 https://clinicaltrials.gov/study/NCT07166094"
X Link 2025-09-10T13:31Z [---] followers, [---] engagements
"Fixed-Duration #Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory #Follicular Lymphoma ORR and complete response (CR) rate were 96% and 88% #Genmab #AbbVie $GMAB $ABBV #Epkinly https://ashpublications.org/blood/article/doi/10.1182/blood.2025029909/547148/Fixed-Duration-Epcoritamab-Plus-R2-Drives https://ashpublications.org/blood/article/doi/10.1182/blood.2025029909/547148/Fixed-Duration-Epcoritamab-Plus-R2-Drives"
X Link 2025-09-11T07:51Z [---] followers, [---] engagements
"$GMAB - Genmab: A Matter Of Time https://seekingalpha.com/article/4822275-genmab-a-matter-of-timesource=tweet https://seekingalpha.com/article/4822275-genmab-a-matter-of-timesource=tweet"
X Link 2025-09-13T05:56Z [---] followers, [---] engagements
"@PersimmonTI could Genmab be a fit"
X Link 2025-09-14T15:22Z [---] followers, [---] engagements
"@AaronRosenblum5 @cIubsandwich070 "Upon strategic evaluation we have decided to discontinue preparation for a Phase [--] study in second / third line squamous cell carcinoma of the head and neck" https://ir.genmab.com/static-files/9babf34b-bff3-40c7-a14c-29214f4f393a https://ir.genmab.com/static-files/9babf34b-bff3-40c7-a14c-29214f4f393a"
X Link 2025-09-19T11:49Z [---] followers, [---] engagements
"@AaronRosenblum5 @cIubsandwich070 no i haven't seen more. It could also be that Pfizer is less interested as they agreed to change the License agreement to transfer some of the Tisotumab responsibilities to Genmab"
X Link 2025-09-19T13:16Z [---] followers, [--] engagements
"New Novartis data further support benefits of #Kesimpta in relapsing MS following switch from oral disease modifying therapies $NVS $GMAB #Genmab https://www.novartis.com/news/media-releases/new-novartis-data-further-support-benefits-kesimpta-relapsing-ms-following-switch-from-oral-disease-modifying-therapiesutm_source=twitter&utm_medium=social&utm_campaign=2025-RMS-Data-ECTRIMS&utm_content=static-image-global"
X Link 2025-09-24T09:18Z [---] followers, [---] engagements
"Dr. Brian Durie provides details of the CASSIOPEIA trial mulitple #myeloma #Daratumumab #Genmab $GMXAY $JNJ key abstracts presented at #ASCO19 and #EHA2019 via @YouTube @IMFmyeloma https://youtu.be/NhuAkDVRAM4 https://youtu.be/NhuAkDVRAM4"
X Link 2019-06-13T13:31Z [---] followers, [--] engagements
"@Slambucket @Rasga @VincentRK @NorthTxMSG @JackMAiello @MyelomaTeacher @mtmdphd @IMFmyeloma @MayoMyeloma Philippe Moreau: "I think that when we are going to use quadruplet combination including CD38 antibodies plus SCT we are going to #cure some young patients" in this interview on #daratumumab + VTd #EHA24 #Genmab #Myeloma https://www.targetedonc.com/news/daratumumab-improves-responses-pfs-in-newly-diagnosed-transplanteligible-myeloma https://www.targetedonc.com/news/daratumumab-improves-responses-pfs-in-newly-diagnosed-transplanteligible-myeloma"
X Link 2019-06-15T08:59Z [---] followers, [--] engagements
"@Orla_McCourt @MichaelodwyerMD @IrishTimes amazing isn't it how can they leave that out 😂 thanks for the link @MichaelodwyerMD #daratumumab seems 'to make every combination better' very interesting to see what the macrophage activation will add #EHA24 #Genmab #JNJ https://www.youtube.com/watchv=yK8YSahrd0w https://www.youtube.com/watchv=yK8YSahrd0w"
X Link 2019-06-15T09:42Z [---] followers, [--] engagements
"@BertrandBio they were disclosed a while ago SITC2018 had abstracts (you can search duobody) Genmab's IR recently said that the reason for PD-L1x4-1BB being slightly further progressed (as the CD40x4-1BB) has to do with prioritization and resource allocation. https://higherlogicdownload.s3.amazonaws.com/SITCANCER/7aaf41a8-2b65-4783-b86e-d48d26ce14f8/UploadedImages/Annual_Meeting_2018/Annual_Meeting/SITC_2018_Abstract_Book.pdf https://higherlogicdownload.s3.amazonaws.com/SITCANCER/7aaf41a8-2b65-4783-b86e-d48d26ce14f8/UploadedImages/Annual_Meeting_2018/Annual_Meeting/SITC_2018_Abstract_Book.pdf"
X Link 2019-06-17T12:02Z [---] followers, [--] engagements
"clinical determinants driving safety and efficacy of #Camidanlumab Tesirine (ADCT301) in relapsed/refractory Classical #Hodgkin #Lymphoma (CHL) ADCT-301 combines #Genmabs HuMax-TAC antibody and ADC Therapeutics PBD-based warhead and linker technology https://onlinelibrary.wiley.com/doi/10.1002/hon.61_2629 https://onlinelibrary.wiley.com/doi/10.1002/hon.61_2629"
X Link 2019-06-17T13:17Z [---] followers, [--] engagements
"In this five-part series that focuses on making sense of multiple #myeloma treatment Dr Brian Durie discussing Frontline Therapy with Dr. Joseph Mikhael and Dr. Philippe Moreau #Genmab $GMXAY $JNJ #Daratumumab #CASSIOPEIA #MAIA via @IMFmyeloma http://www.myeloma.org/node/2310 http://www.myeloma.org/node/2310"
X Link 2019-06-18T11:52Z [---] followers, [--] engagements
"#SITC2020: #GEN1046 or #DuoBody-PD-L1x4-1BB is jointly developed by #Genmab and #BioNTech using Genmabs DuoBody technology. It is designed to simultaneously block the PD-L1 axis and activate T-cells through conditional 4-1BB co-stimulation $GMAB $BNTX https://www.youtube.com/watchv=QmnXu-ZcoHM https://www.youtube.com/watchv=QmnXu-ZcoHM"
X Link 2020-11-09T14:14Z [---] followers, [--] engagements
"#Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death #Seagen CMO: "Our vedotin-based ADC research at #SITC2020 illustrates the impact of immunogenic cell death on the tumor microenvironment" $GMAB #Genmab $SGEN https://jitc.bmj.com/content/8/Suppl_3/A653 https://jitc.bmj.com/content/8/Suppl_3/A653"
X Link 2020-11-09T14:49Z [---] followers, [--] engagements
"#SITC2020 [---] Preclinical mechanism of action and pharmacodynamic biomarker studies of #DuoBody-CD3x5T4 in vitro and in vivo in solid cancer models $GMAB #Genmab $ABBV https://jitc.bmj.com/content/8/Suppl_3/A746 https://jitc.bmj.com/content/8/Suppl_3/A746"
X Link 2020-11-09T15:01Z [---] followers, [--] engagements
"@Genmab @biontech @Genmab please note that BioNTech already disclosed the updated data via their SEC filings https://investors.biontech.de/sec-filings/sec-filing/6-k/0001564590-20-052594 https://investors.biontech.de/sec-filings/sec-filing/6-k/0001564590-20-052594"
X Link 2020-11-10T08:10Z [---] followers, [--] engagements
"New #Epcoritamab trial by #Genmab & #AbbVie: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic #Leukemia $GMAB $ABBV #DuoBody-CD3xCD20 #GEN3013 #CLL https://www.clinicaltrials.gov/ct2/show/NCT04623541term=NCT04623541&draw=2&rank=1 https://www.clinicaltrials.gov/ct2/show/NCT04623541term=NCT04623541&draw=2&rank=1"
X Link 2020-11-10T12:57Z [---] followers, [--] engagements
"#Genmab and #BioNTech started the dose expansion for #GEN1046 (#DuoBody-PD-L14-1BB) in NSCLC It looks like [--] cohorts are planned 2x NSCLC Urothelial Endometrial Triple-negative breast cancer Squamous Cell Carcinoma of the Head and Neck and Cervical $GMAB $BNTX #BNT311"
X Link 2020-11-10T15:14Z [---] followers, [--] engagements
"Next-Generation Bispecific Antibody Shows Early Clinical Activity in Advanced Solid Tumors #Genmab and #BioNTech show early data on #GEN1046 (#DuoBody-PD-L14-1BB) at #SITC2020 $GMAB $BNTX #BNT311 via @onclive https://www.onclive.com/view/next-generation-bispecific-antibody-shows-early-clinical-activity-in-advanced-solid-tumors https://www.onclive.com/view/next-generation-bispecific-antibody-shows-early-clinical-activity-in-advanced-solid-tumors"
X Link 2020-11-13T08:01Z [---] followers, [--] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing